

The Brief Pain Inventory User Guide



Charles S. Cleeland, PhD

Copyright and Terms of Use

The Brief Pain Inventory (BPI) copyright is held by Dr. Charles S. Cleeland (1991). The copyright applies to the BPI and all its derivatives in any language.

The BPI may not be used or reproduced without permission from Charles S. Cleeland, PhD, or his designee. Fees for use may apply.

The BPI may not be modified or translated into another language without the express written consent of the copyright holder. Failure to comply may result in legal action. Permission to alter or translate the instrument may be obtained by contacting Dr. Charles S. Cleeland either by e-mail at symptomresearch@mdanderson.org or by mail at:

Charles S. Cleeland, PhD
Professor and Chair, Department of
Symptom Research
The University of Texas M. D. Anderson
Cancer Center
1515 Holcombe Boulevard, Unit 1450
Houston, Texas 77030

Visit [www.mdanderson.org/departments/prg/Assessment Tools > Brief Pain Inventory](http://www.mdanderson.org/departments/prg/AssessmentTools/BriefPainInventory) for more information.

© 2009 Charles S. Cleeland
All rights reserved

Table of Contents

Chapter 1.....	1
Development of the Brief Pain Inventory	1
Background.....	1
Developing a Measurement Model and Items	2
Test Construction Standards.....	3
Measurement Conceptualization: Multiple Dimensions of Pain	3
Early Version: The Wisconsin Brief Pain Questionnaire.....	5
The Brief Pain Inventory.....	6
Scoring the Brief Pain Inventory as an Outcome Measure	7
Psychometric Properties of the Brief Pain Inventory.....	8
References	11
Chapter 2.....	15
BPI References: Use of the BPI in Various Studies	15
Cancer Bone Pain.....	16
Cancer Epidemiology	20
Cancer Pain	21
Depressive Disorders	31
Fabry Disease	32
Fibromyalgia.....	33
HIV/AIDS	34
Minority Studies.....	35
Neuromuscular Pain.....	36
Neuropathic Pain.....	40
Osteoarthritis and Other Joint Diseases.....	42
Psychosocial Studies.....	45
Surgical and Procedural Pain.....	46
Validation Studies	49
Language Translations.....	58
Methods Papers	59

Chapter 1

Development of the Brief Pain Inventory

The Brief Pain Inventory (BPI) has become one of the most widely used measurement tools for assessing clinical pain. The BPI allows patients to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function. Initially developed to assess pain related to cancer, the BPI has been shown to be an appropriate measure for pain caused by a wide range of clinical conditions. The BPI has been used in hundreds of studies. In some ways, the BPI is a "legacy" instrument—a self-report measure that has, over time, become a standard for the assessment of pain and its impact.

Background

In the late 1970s, it became increasingly evident that patients with cancer, especially the later stages of the disease, experienced incapacitating pain that was often poorly controlled. A constellation of events—the publishing of opinion pieces by prominent persons with cancer pain, the increasing advocacy of pain professionals and organizations for better cancer pain management, a growing awareness of the problem by national and international policy groups, and the simple recognition that pain often could be controlled—created the climate for a sustained effort to improve pain management for those with cancer.

A first step in this effort was to document the extent of poor pain management. The National Cancer Institute (NCI) and the Cancer Unit of the World Health Organization (WHO) wanted measurement instruments that would better capture the severity and impact of cancer pain and measure improvement in pain after changes in analgesic practice or implementation of new pain treatments. These instruments also needed to function well in large-scale national and international studies of the epidemiology of cancer pain.

With grant support from both the NCI and the WHO, the Pain Research Group at the University of Wisconsin Medical School-Madison, under the direction of Charles S. Cleeland, PhD, undertook a program to test and develop self-report measures of cancer pain and to apply them to studies of pain and its treatment in the United States and internationally. The Pain Research Group, now the Department of Symptom Research at The University of Texas M. D. Anderson Cancer Center, was also the WHO Collaborating Center for Symptom Research in Cancer.

Developing a Measurement Model and Items

Several existing pain measures (such as the McGill Pain Questionnaire; Melzack, 1975) were field-tested in interviews with cancer patients who had pain (N=50). Almost all of these measures had been designed to assess pain in patients with nonmalignant disease. The patients reported that the measures were too complex and too long, making them excessively burdensome for patients with high levels of pain. Patients also noted that the existing instruments included items not relevant to cancer patients and sometimes required responses that patients felt were ambiguous (Cleeland, 1984). Patients were also asked what questions they felt were the most important for communicating their experience of pain. The results of this study made clear that a new measurement instrument was needed.

The Pain Research Group planned a program to develop such an instrument. The aims were to have a scale that: (a) would take only a short time to complete; (b) would be easy for patients to understand; (c) could be self-administered for literate patients, or be completed by interview for illiterate or low-literacy patients; (d)

would be easily translated for non-English-speaking patients; and (e) would capture not only pain severity, but also the perception of how pain interfered with daily life.

Test Construction Standards

As a guide to scale construction, we used then-current psychometric standards found in the *Standards for Educational and Psychological Tests* published by the American Psychological Association, American Educational Research Association, and the National Council on Measurement in Education (1974). These standards included common elements of test validity (content, criterion, and construct) and reliability (internal consistency and test-retest). These standards had not been systematically applied in the development of the existing pain report scales.

Measurement Conceptualization: Multiple Dimensions of Pain


That pain is multidimensional was made clear during our patient interviews: patients reported that an adequate representation of pain required more than one simple measure of pain intensity. Melzack and Casey (1968) suggested that, based on the underlying neurophysiological mechanisms of pain, pain assessment should include three dimensions: sensory-discriminative, motivational-affective, and cognitive-evaluative. This approach to self-report measurement relied on three distinct patterns of responses to the words that patients used to describe their pain. However, the patients we interviewed had difficulty discriminating between the motivational-affective and cognitive-evaluative dimensions (Cleeland, 1989; Cleeland, 1990).

More commonly, researchers have found that two dimensions of pain self-report account for most of the variability in the way patients describe pain. Beecher (1959) called these dimensions “pain” and “reaction to pain”; Clark and Yang (1983) called them “sensory-discriminative” and “attitudinal.” Following Beecher, we called these dimensions “sensory” and “reactive” (Cleeland, 1989).

Accordingly, our new questionnaire was developed to include items that reported the “sensory” dimension of pain (intensity, or severity) and the “reactive” dimension of pain (interference with

daily function). We constructed four items to capture the variability of pain over time: pain at its “worst,” “least,” “average,” and “now” (current pain). On the basis of patient interviews from additional field testing, we chose seven items that measured how much pain interfered with various daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. Two subdimensions of pain interference were proposed: an affective subdimension (REM: relations with others, enjoyment of life, and mood) and an activity subdimension (WAW: walking, general activity, and work). The appropriate categorization of sleep within these two subdimensions was unclear.

A graphic representation of the conceptual framework for our measurement model is shown below. The model conforms to the U.S. Food and Drug Administration’s *Draft Guidance for Industry, Patient-reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims* (Food and Drug Administration, 2006).



Early Version: The Wisconsin Brief Pain Questionnaire

The first version of our pain measure was the Wisconsin Brief Pain Questionnaire (BPQ; Daut & Cleeland, 1982; Daut, Cleeland, & Flanery, 1983). In the initial phase of scale development, 667 patients with cancer and 32 patients with rheumatoid arthritis were administered a three-page questionnaire and interviewed about the basic parameters of their pain (Daut et al., 1982). Patients who had experienced pain in the last month were asked to rate their pain intensity at its "worst," "average," and "now" and to rate the extent to which pain had interfered with activity and enjoyment of life. Patients were also asked to mark their pain location(s) on front/back body diagrams and to describe their perception of the cause of pain, the types of pain treatment they were receiving, and the amount of relief provided by their treatment. Patients were also asked to describe the quality of their pain by choosing words among a list of verbal descriptors derived from the McGill Pain Questionnaire (Melzack, 1975).

The design of the four-page BPQ was based on this initial questionnaire. In the BPQ, a 0–10 numerical rating scale was used to measure three pain severity items: "worst" in the past month, "average," and "now," where 0=no pain and 10=pain as bad as you can imagine. The interference items were measured using a five-option verbal descriptor scale, with ratings of 0=not at all, 1=a little bit, 2=moderately, 3=quite a bit, and 4=extremely. The recall period for both severity and interference scales was "in the last week." The BPQ also retained the body diagram from the initial questionnaire, along with word descriptors of pain quality and questions about types and effectiveness of pain treatment, the patient's perception of the cause of pain, and certain demographic information.

A second study (Daut et al., 1983) investigated the psychometric properties of the BPQ. This set of analyses was based on BPQ data obtained from more than 1200 patients with cancer at The University of Wisconsin Cancer Center. To determine test-retest characteristics of the BPQ, subsamples of patients completed the BPQ on two or more occasions. For comparison with other disease sites, a sample of patients with pain from rheumatoid arthritis was also surveyed.

Most of the patients were able to complete the BPQ by themselves with little or no instruction; others were interviewed to complete the questionnaire. A subset 25 patients completed both an interview-administered and self-administered version of the survey in counterbalanced order. We found little difference in ratings due to mode of administration. As expected, test-retest reliability varied by item. Short (days) test-retest reliability was 0.93 for "worst pain," but only 0.59 for "pain now." Preliminary exploration found that patient-reported pain severity and interference were directly associated with the use of opioid analgesics and the severity of disease.

The Brief Pain Inventory

The next iteration of our pain measure was the [long form](#) of the Brief Pain Inventory (BPI; Cleeland, 1989; Cleeland, 1990; Cleeland, 1991; Cleeland & Ryan, 1994). In this new instrument, we added the item "least pain" to the severity items and dropped the categorical rating scale for the interference items, in response to patient preference. The interference items were now presented with 0–10 scales, with 0=no interference and 10=interferes completely. The initial version of the BPI used a recall period of one week for both pain severity and pain interference ratings, included questions about medication use, and asked the patient to check potential pain quality descriptors that may describe their pain. The BPI long form also asked questions about the percentage and duration of pain relief and nonmedical methods used to relieve pain.

This version of the BPI proved to be too lengthy for repeated use in clinical monitoring or as a repeated measure in research. As a result, we developed a [shorter version](#) of the BPI. This version of the BPI retained the front and back body diagrams, the four pain severity items and seven pain interference items rated on 0–10 scales, and the question about percentage of pain relief by analgesics. The most important difference between the longer and shorter versions of the BPI is that the latter uses a 24-hour recall period.

Whereas the BPI long form is still used as a baseline measure in clinical trials, the shorter version has become the standard for use

in clinical and research applications. The short form is typically what is referred to when the BPI is cited in research, and it is the version we describe below. Most psychometric evaluations of the BPI have been performed on the short form.

Scoring the Brief Pain Inventory as an Outcome Measure

A recent consensus panel recommended that the two domains measured by the BPI— pain intensity (severity) and the impact of pain on functioning (interference)— be included as outcomes in all chronic-pain clinical trials (IMMPACT, Turk et al., 2003). The IMMPACT panel (www.immpact.org) specifically identified the interference items of the BPI, rated on a 0–10 scale, as one of the two scales recommended for assessment of pain-related functional impairment (Dworkin et al., 2005).

How to Score the BPI: Pain Severity

The BPI assesses pain at its “worst,” “least,” “average,” and “now” (current pain). In clinical trials, the items “worst” and “average” have each been used singly to represent pain severity. A composite of the four pain items (a mean severity score) is sometimes presented as supplemental information. The use of these single items is supported by the IMMPACT recommendations for assessing pain in clinical trials (Dworkin et al., 2005; Turk et al., 2006; Dworkin et al., 2008) and by the FDA Draft Guidance for Industry: Patient-Reported Outcome Measures (Food and Drug Administration, 2006). However, the BPI’s developers recommend that all four severity items be used, because the models for validation of the BPI included all four items.

How to Score the BPI: Pain Interference

The BPI measures how much pain has interfered with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. BPI pain interference is typically scored as the mean of the seven interference items. This mean can be used if more than 50%, or four of seven, of the total items have been completed on a given administration.

We are exploring the utility of scoring the activity and affective dimensions described above (WAW and REM, see diagram [\[link\]](#)) as arithmetic means of these sets of items.

How to Score the BPI: Other Items

The item, “Throughout our lives, most of us have had pain from time to time (such as minor headaches, sprains, and toothaches). Have you had pain other than these everyday kinds of pain today?” is a YES/NO preliminary screening question at the beginning of the BPI. This item is optional and we have not evaluated its psychometric properties. The BPI also asks the patient to indicate the percentage of relief provided by pain treatments or medications, but we have not found this item to be very useful in our studies.

Psychometric Properties of the Brief Pain Inventory

Dimensions of the BPI: Two-Factor Structure

Several approaches have explored the underlying dimensions of the BPI. As described above, the BPI was designed to capture two dimensions of pain: severity and interference. The BPI was also intended to capture two components of interference— *activity* and *affect* (emotions).

One of the first studies of the dimensions of the BPI compared the factor structure of four language versions of the BPI used to assess cancer pain in the United States, Mexico, the Philippines, and Vietnam (Cleeland, 1990). Factor analysis was applied to the matrix of intercorrelations of the item scores of each sample. For each language version, the same two factors emerged with an eigenvalue greater than 1: the first factor comprised the pain interference items and the second factor comprised the pain severity items. The similarity of the factor loading among the language versions indicated that patients experiencing cancer and pain, living in various countries and speaking various languages, responded to the items in a similar fashion.

This two-factor structure was confirmed in a large national study conducted in the U.S. by the Eastern Cooperative Oncology Group. Outpatients (N= 1261) with recurrent or metastatic cancer

from 80 centers were enrolled in the study (Cleeland et al., 1994). Factor analysis verified the two separate factors, pain severity and interference, found in the previous study. Internal stability (Cronbach alpha) was also examined in this study. Alphas showed good internal consistency, ranging from 0.80 to 0.87 for the four pain severity items and from 0.89 to 0.92 for the seven interference items. Subsequent data from studies of cancer patients in many countries and many languages have demonstrated high internal consistency and the robust nature of these two dimensions of the BPI.

Dimensions of the BPI: Multidimensional Scaling of Interference

We have also used multidimensional scaling (MDS) to examine the dimensions of the BPI. We used a four-country sample with BPI responses from patients with cancer and pain (Cleeland et al., 1996). In this MDS analysis, we focused on only the interference items of the survey. Our purpose was to explore potential linguistic and cultural differences in the report of pain interference.

As we had hypothesized, two dimensions of the interference scale were demonstrated. The first dimension consisted of patients' ratings of pain's interference with enjoyment of life, mood, and relations with others (REM, the affective cluster of interference items). A second dimension of interference ratings consisted of patients' ratings of pain's interference with walking, general activity, work, and sleep (WAW, the activity cluster of interference items). Subsequent studies of additional language versions (Hindi in Saxena, Mendoza, & Cleeland, 1999; Norwegian in Klepstad et al., 2002) have shown a similar decomposition of the interference items into the affective (REM) and activity (WAW) interference subscales.

In summary, there is strong psychometric support for the independent measurement of pain severity and interference in the BPI. In addition, there is provisional evidence that the interference items independently measure activity and affective interference.

Test-Retest Reliability

Values from any measure should not differ significantly between assessments. The underlying concept of a measure should not change between assessments. This psychometric concept applies to patient-report instruments and is examined by test-retest reliability.

The test-retest reliability of the BPI has been studied in cancer patients and other patients with pain. Initial short-term (1 day to 1 week) reliability for ratings of pain "worst" (0.93) and "usual" or "average" pain (0.78) in patients with cancer was high, which signals acceptable reliability. As expected, test-retest reliability for pain "now" severity ratings were lower (0.59), because pain intensity often changes over time (Daut et al., 1983).

Several more recent studies have found similar test-retest coefficients for these items. For example, Radbruch et al. (1999) examined test-retest coefficients in 109 outpatients in a German pain clinic, with the retest occurring 30 to 60 minutes after the first administration. Test-retest values were 0.98 for pain severity and 0.97 for pain interference. The individual item with the lowest value, 0.78, was pain "least."

Reliabilities have also been examined with daily administration of the BPI. In patients with osteoarthritis (Mendoza et al., 2006), test-retest reliabilities of pain severity (pain "worst," "average," and "current") between consecutive daily administration for a week showed correlations ranging from 0.83 to 0.88. The test-retest reliabilities for pain interference ranged from 0.83 to 0.93, beginning at day 1 for the week.

In another study of patients who underwent coronary artery bypass graft, the test-retest reliability coefficients for pain severity ranged from 0.72 to 0.95 during assessment periods where postsurgical pain declined in an expected direction (Mendoza et al., 2004). Similarly, the test-retest reliability coefficients for pain interference ranged from 0.81 to 0.93 during the same assessment period.

Test-Retest Reliability and Alternate-Forms Reliability: the Hindi Translation

Finally, one study combined an examination of both test-retest reliability and alternate-forms reliability (Saxena et al., 1999). In this study, 100 patients with cancer who spoke both English and Hindi completed both language versions of the BPI on different days in a counterbalanced design. In addition to reporting reliability based on internal consistency, the study design allowed calculation of the alternate-forms reliability of the BPI. Treating the Hindi and English versions of the BPI as alternate test forms, the alternate-form reliabilities of the interference and severity subscales were 0.88 and 0.95, respectively. These reliabilities demonstrated that the Hindi and English versions could be substituted for one another in assessing the severity of pain and its impact in bilingual patients. These data also provided support for the high test-retest reliability of the BPI.

In summary, the BPI is reliable to the extent that high test-retest reliability and alternate-form reliability is demonstrated when pain is stable or when pain changes in a predictable way.

References

- American Psychological Association, American Educational Research Association, National Council on Measurement in Education. *Standards for Educational and Psychological Tests*. Washington DC: 1974.
- Cleeland CS. The impact of pain on the patient with cancer. *Cancer* 54(11 Suppl): 2635-2641, 12/1984.
- Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, editors. *Issues in Pain Measurement*. New York: Raven Press; pp. 391-403, 1989 *Advances in Pain Research and Therapy*; Vol. 12.
- Cleeland CS. Assessment of pain in cancer: measurement issues. In: Foley KM, Bonica JJ, Ventafridda V, editors. *Proceedings of the Second International Congress on Cancer Pain*. New York: Raven Press; pp. 47-55, 1990 *Advances in Pain Research and Therapy*; Vol. 16.
- Cleeland CS. Pain assessment in cancer. In: Osoba D, editor. *Effect of Cancer on Quality of Life*. Boca Raton: CRC Press, Inc.; pp. 293-305, 1991.
- Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. *N Engl J Med* 330(9): 592-596, 3/1994.
- Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. *Pain* 67(2-3): 267-273, 10/1996.
- Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singapore* 23(2): 129-138, 3/1994.
- Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. *Cancer* 50(9): 1913-1918, 11/1982.
- Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. *Pain* 17(2): 197-210, 10/1983.
- Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain* 113(1-2): 9-19, 1/2005.
- Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von ST, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain

- clinical trials: IMMPACT recommendations. *J Pain* 9(2): 105-121, 2/2008.
- Food and Drug Administration. Guidelines for Industry (draft). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2006. Rockville MD, U.S. Department of Health and Human Services. Ref Type: Report
- Klepstad P, Loge JH, Borchgrevink PC, Mendoza TR, Cleeland CS, Kaasa S. The Norwegian Brief Pain Inventory questionnaire: translation and validation in cancer pain patients. *J Pain Symptom Manage* 24(5): 517-525, 11/2002.
- Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. *Pain* 1(3): 277-299, 9/1975.
- Melzack R, Casey KL. Sensory, motivational, and central control determinants of pain: a new conceptual model. In: Kenshalo DR, editor. *The Skin Senses Proceedings*. Springfield IL: Thomas; pp. 423-439, 1968.
- Mendoza T, Mayne T, Rublee D, Cleeland C. Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. *Eur J Pain* 10(4): 353-361, 5/2006.
- Mendoza TR, Chen C, Brugger A, Hubbard R, Snabes M, Palmer SN, Zhang Q, Cleeland CS. The utility and validity of the modified Brief Pain Inventory in a multiple-dose postoperative analgesic trial. *Clin J Pain* 20(5): 357-362, 9/2004.
- Radbruch L, Loick G, Kiencke P, Lindena G, Sabatowski R, Grond S, Lehmann KA, Cleeland CS. Validation of the German version of the Brief Pain Inventory. *J Pain Symptom Manage* 18(3): 180-187, 9/1999.
- Saxena A, Mendoza T, Cleeland CS. The assessment of cancer pain in north India: the validation of the Hindi Brief Pain Inventory--BPI-H. *J Pain Symptom Manage* 17(1): 27-41, 1/1999.
- Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland CS, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Witter J. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. *Pain* 106: 337-345, 2003.
- Turk DC, Dworkin RH, Burke LB, Gershon R, Rothman M, Scott J, Allen RR, Atkinson JH, Chandler J, Cleeland C, Cowan P, Dimitrova R, Dionne R, Farrar JT, Haythornthwaite JA, Hertz S, Jadad AR, Jensen MP, Kellstein D, Kerns RD, Manning DC, Martin S, Max MB, McDermott MP, McGrath P, Moulin DE, Nurmikko T, Quessy S, Raja S, Rappaport BA, Rauschkolb C, Robinson JP, Royal MA, Simon L, Stauffer JW, Stucki G, Tollett J, von ST, Wallace MS, Wernicke J, White RE, Williams AC, Witter J, Wyrwich KW. Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. *Pain* 125(3): 208-215, 12/2006.

Chapter 2

BPI References: Use of the BPI in Various Studies

The Brief Pain Inventory has been used in more than 400 studies worldwide. Here we present BPI references categorized by type of study.

Cancer Bone Pain	16
Cancer Epidemiology	20
Cancer Pain	21
Depressive Disorders	31
Fabry Disease	32
Fibromyalgia	33
HIV/AIDS	34
Minority Studies	35
Neuromuscular Pain	36
Neuropathic Pain.....	40
Osteoarthritis and Other Joint Diseases.....	42
Psychosocial Studies.....	45
Surgical and Procedural Pain	46
Validation Studies	49
Language Translations.....	58
Methods Papers.....	59

Cancer Bone Pain

1. Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. *Cancer* 101(10): 2202-2208, 11/2004.
2. Borden LS, Jr., Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, Mohler M, Torti FM. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. *Cancer* 107(5): 1093-1100, 9/2006.
3. Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Wong GY, Sloan JA, Novotny PJ, Lewis BD, Welch TJ, Farrell MA, Maus TP, Lee RA, Reading CC, Petersen IA, Pickett DD. Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. *Radiology* 224(1): 87-97, 7/2002.
4. Callstrom MR, Atwell TD, Charboneau JW, Farrell MA, Goetz MP, Rubin J, Sloan JA, Novotny PJ, Welch TJ, Maus TP, Wong GY, Brown KJ. Painful metastases involving bone: percutaneous image-guided cryoablation--prospective trial interim analysis. *Radiology* 241(2): 572-580, 11/2006.
5. Carrafiello G, Lagana D, Ianniello A, Nicotera P, Fontana F, Dizonno M, Cuffari S, Fugazzola C. Radiofrequency thermal ablation for pain control in patients with single painful bone metastasis from hepatocellular carcinoma. *Eur J Radiol: e-pub ahead of print*, 5/2008.
6. Castel LD, Saville BR, Depuy V, Godley PA, Hartmann KE, Abernethy AP. Racial differences in pain during 1 year among women with metastatic breast cancer: a hazards analysis of interval-censored data. *Cancer* 112(1): 162-170, 1/2008.
7. Chow E, Loblaw A, Harris K, Doyle M, Goh P, Chiu H, Panzarella T, Tsao M, Barnes EA, Sinclair E, Farhadian M, Danjoux C. Dexamethasone for the prophylaxis of radiation-

- induced pain flare after palliative radiotherapy for bone metastases-a pilot study. *Support Care Cancer* 15(6): 643-647, 6/2007.
8. Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient's experience. *Clin Cancer Res* 12(20 Pt 2): 6236s-6242s, 10/2006.
 9. Colella J, Scrofine S, Galli B, Knorr-Mulder C, Gejerman G, Scheuch J, Lanteri V, Siegel A, Levey S, Watson R, Block M, Sawczuk I. Prostate HDR radiation therapy: a comparative study evaluating the effectiveness of pain management with peripheral PCA vs. PCEA. *Urol Nurs* 26(1): 57-61, 2/2006.
 10. Depuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. *Support Care Cancer* 15(7): 869-876, 7/2007.
 11. Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, Wong GY, Sloan JA, Novotny PJ, Petersen IA, Beres RA, Regge D, Capanna R, Saker MB, Gronemeyer DH, Gevarguez A, Ahrar K, Choti MA, de Baere TJ, Rubin J. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. *J Clin Oncol* 22(2): 300-306, 1/2004.
 12. Hadi S, Fan G, Hird AE, Kirou-Mauro A, Filipczak LA, Chow E. Symptom clusters in patients with cancer with metastatic bone pain. *J Palliat Med* 11(4): 591-600, 5/2008.
 13. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. *J Clin Oncol* 26(15): 2544-2549, 5/2008.
 14. Harris K, Pugash R, David E, Yee A, Sinclair E, Myers J, Chow E. Percutaneous cementoplasty of lytic metastasis in left acetabulum. *Curr Oncol* 14(1): 4-8, 2/2007.
 15. Harris K, Li K, Flynn C, Chow E. Worst, average or current pain in the brief pain inventory: Which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? *Clinical Oncology* 19(7): 523-527, 9/2007.
 16. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, III, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. *J Natl Cancer Inst* 97(11): 798-804, 6/2005.
 17. Hong SJ, Cho KS, Choi HY, Ahn H, Kim CS, Chung BH. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer. *Yonsei Medical Journal* 48(6): 1001-1008, 12/2007.
 18. Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R, Theriault R, Martin C, Yasko A. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. *J Pain Symptom Manage* 16(3): 171-178, 9/1998.
 19. Kornblith AB, Herndon JE, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. *Ann Oncol* 12(5): 633-641, 5/2001.
 20. Loblaw A, Chow E, Panzarella T, Tsao M, Barnes EA, Sinclair E, Farhadian M, Danjoux C. Dexamethasone for the prophylaxis of radiation-induced pain flare following palliative radiotherapy for bone metastases. *Int J Radiat Oncol Biol Phys* 66(3 Supplement 1): S525, 11/2006.
 21. Lothman H, Heatley S, Lipton A. Zoledronic acid (zol) provides long-term palliation of bone pain in breast cancer (bc) patients (pts) with bone metastases. *Eur J Oncol Nurs* 10(3): 225-226, 7/2006.
 22. Mystakidou K, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiatas ML, Galanos A, Vlahos L. A prospective randomized controlled clinical trial of zoledronic acid for bone metastases. *Am J Hosp Palliat Care* 23(1): 41-50, 1/2006.
 23. Nishio M, Sano M, Tamaki Y, Fujii H, Shima Y, Fujimoto H, Kubo A, Koizumi K, Tokuda Y, Adachi S, Sumiyoshi Y, Hasegawa T, Eguchi K. [A multicenter study to determine the efficacy and safety of strontium (89Sr) chloride for palliation of painful bony

metastases in cancer patients]. *Nippon Igaku Hoshasen Gakkai Zasshi* 65(4): 399-410, 10/2005.

24. Pisteveu-Gompaki K, Kouloulis VE, Varveris C, Mystakidou K, Georgakopoulos G, Eleftheriadis N, Gompakis N, Kouvaris J. Radiotherapy plus either transdermal fentanyl or paracetamol and codeine for painful bone metastases: a randomised study of pain relief and quality of life. *Curr Med Res Opin* 20(2): 159-163, 2004.
25. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. *Clin Prostate Cancer* 4(1): 31-37, 6/2005.
26. Tester W, Ackler J, Tijani L, Leighton J. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. *Cancer J* 12(4): 299-304, 7/2006.
27. Thanos L, Mylona S, Galani P, Tzavoulis D, Kalioras V, Tanteles S, Pomoni M. Radiofrequency ablation of osseous metastases for the palliation of pain. *Skeletal Radiol* 37(3): 189-194, 3/2008.
28. Vassiliou V, Kalogeropoulou C, Christopoulos C, Solomou E, Leotsinides M, Kardamakis D. Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment. *Int J Radiat Oncol Biol Phys* 67(1): 264-272, 1/2007.
29. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. *Br J Cancer* 92(10): 1869-1876, 5/2005.
30. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. *Ann Oncol* 17(6): 986-989, 6/2006.
31. Wu JS, Monk G, Clark T, Robinson J, Eigel BJ, Hagen N. Palliative radiotherapy improves pain and reduces functional

interference in patients with painful bone metastases: a quality assurance study. *Clin Oncol (R Coll Radiol)* 18(7): 539-544, 9/2006.

32. Yamada K, Kohno N. [Efficacy of bisphosphonates for bone pain control]. *Nippon Rinsho* 65(1): 152-156, 1/2007.

Cancer Epidemiology

1. Beck SL, Falkson G. Prevalence and management of cancer pain in South Africa. *Pain* 94(1): 75-84, 10/2001.
2. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. *N Engl J Med* 330(9): 592-596, 3/1994.
3. Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ. Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. *Ann Intern Med* 127(9): 813-816, 11/1997.
4. Costantini M, Viterbori P, Flego G. Prevalence of pain in Italian hospitals: results of a regional cross-sectional survey. *J Pain Symptom Manage* 23(3): 221-230, 3/2002.
5. Crosby FE, Colestro J, Ventura MR, Graham K. Survey of pain among veterans in western New York. *Pain Manag Nurs* 7(1): 12-22, 3/2006.
6. Enting RH, Oldenmenger WH, Van Gool AR, van der Rijt CC, Sillevs Smitt PA. The effects of analgesic prescription and patient adherence on pain in a Dutch outpatient cancer population. *J Pain Symptom Manage* 34(5): 523-531, 11/2007.
7. Everdingen MHJV, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. *Pain* 132(3): 312-320, 12/2007.
8. Garbez RO, Chan GK, Neighbor M, Puntillo K. Pain after discharge: a pilot study of factors associated with pain management and functional status. *Journal of Emergency Nursing* 32(4): 288-293, 8/2006.

9. Holtan A, Aass N, Nordoy T, Haugen DF, Kaasa S, Mohr W, Kongsgaard UE. Prevalence of pain in hospitalised cancer patients in Norway: a national survey. *Palliat Med* 21(1): 7-13, 1/2007.
10. Kongsgaard UE, Holtan A, Aass N. Prevalence of cancer pain in outpatients at a Norwegian comprehensive cancer centre. *European Journal of Pain* 10(Supplement 1): S247, 9/2006.
11. Mystakidou K, Parpa E, Katsouda E, Galanos A, Vlahos L. Pain and desire for hastened death in terminally ill cancer patients. *Cancer Nurs* 28(4): 318-324, 7/2005.
12. Rabow MW, Dibble SL. Ethnic differences in pain among outpatients with terminal and end-stage chronic illness. *Pain Med* 6(3): 235-241, 5/2005.
13. Shin H, Kim K, Young HK, Chee W, Im EO. A comparison of two pain measures for Asian American cancer patients. *West J Nurs Res* 30(2): 181-196, 3/2008.
14. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van KM, Patijn J. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. *Pain* 132(3): 312-320, 12/2007.

Cancer Pain

1. Aulet K, Roger GC, Ilett KF, Page-Sharp M, Boyd F, Oh TE. Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. *Ther Drug Monit* 28(3): 359-366, 6/2006.
2. Beck SL, Dudley WN, Barsevick A. Pain, sleep disturbance, and fatigue in patients with cancer: using a mediation model to test a symptom cluster. *Oncol Nurs Forum* 32(3): 542, 5/2005.
3. Burckhardt CS, Jones KD. Effects of chronic widespread pain on the health status and quality of life of women after breast cancer surgery. *Health Qual Life Outcomes* 3: 30, 2005.
4. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on

Cancer Pain. International Association for the Study of Pain. *Pain* 82(3): 263-274, 9/1999.

5. Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, Jackson KA, Lickiss N, Muirden N, Pisasale M, Moulin D, Schulz VN, Rico Pazo MA, Serrano JA, Andersen H, Henriksen HT, Mejholm I, Sjogren P, Heiskanen T, Kalso E, Pere P, Poyhia R, Vuorinen E, Tigerstedt I, Ruismaki P, Bertolino M, Larue F, Ranchere JY, Hege-Scheuing G, Bowdler I, Helbing F, Kostner E, Radbruch L, Kastrinaki K, Shah S, Vijayaram S, Sharma KS, Devi PS, Jain PN, Ramamani PV, Beny A, Brunelli C, Maltoni M, Mercadante S, Plancarte R, Schug S, Engstrand P, Ovalle AF, Wang X, Alves MF, Abrunhosa MR, Sun WZ, Zhang L, Gazizov A, Vaisman M, Rudoy S, Gomez SM, Vila P, Trelis J, Chaudakshetrin P, Koh ML, Van Dongen RT, Vielvoye-Kerkmeier A, Boswell MV, Elliott T, Hargus E, Lutz L. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. *Palliat Med* 18(3): 177-183, 4/2004.
6. Carpenter JS, Sloan P, Andrykowski MA, McGrath P, Sloan D, Rexford T, Kenady D. Risk factors for pain after mastectomy/lumpectomy. *Cancer Pract* 7(2): 66-70, 3/1999.
7. Chang MC, Chang YC, Chiou JF, Tsou TS, Lin CC. Overcoming patient-related barriers to cancer pain management for home care patients. A pilot study. *Cancer Nurs* 25(6): 470-476, 12/2002.
8. Chang VT, Hwang SS, Feuerman M, Kasimis BS. Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment. *Cancer* 88(5): 1175-1183, 3/2000.
9. Chang VT, Hwang SS, Kasimis B. Longitudinal documentation of cancer pain management outcomes: a pilot study at a VA medical center. *J Pain Symptom Manage* 24(5): 494-505, 11/2002.
10. Cleeland CS, Portenoy RK, Rue M, Mendoza TR, Weller E, Payne R, Kirshner J, Atkins JN, Johnson PA, Marcus A. Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern

Cooperative Oncology Group. *Ann Oncol* 16(6): 972-980, 6/2005.

11. Du Pen SL, Du Pen AR, Polissar N, Hansberry J, Kraybill BM, Stillman M, Panke J, Everly R, Syrjala K. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. *J Clin Oncol* 17(1): 361-370, 1/1999.
12. Elliott BA, Elliott TE, Murray DM, Braun BL, Johnson KM. Patients and family members: the role of knowledge and attitudes in cancer pain. *J Pain Symptom Manage* 12(4): 209-220, 10/1996.
13. Esnaola NF, Cantor SB, Johnson ML, Mirza AN, Miller AR, Curley SA, Crane CH, Cleeland CS, Janjan NA, Skibber JM. Pain and quality of life after treatment in patients with locally recurrent rectal cancer. *J Clin Oncol* 20(21): 4361-4367, 11/2002.
14. Ferrell BR, Grant MM, Funk BM, Otis-Green SA, Garcia NJ. Quality of life in breast cancer survivors: implications for developing support services. *Oncol Nurs Forum* 25(5): 887-895, 6/1998.
15. Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. *Curr Med Res Opin* 20(6): 911-918, 6/2004.
16. Gulluoglu BM, Cingi A, Cakir T, Gercek A, Barlas A, Eti Z. Factors related to post-treatment chronic pain in breast cancer survivors: the interference of pain with life functions. *Int J Fertil Womens Med* 51(2): 75-82, 3/2006.
17. Holtan A, Kongsgaard UE, Ohnstad HO. [Cancer pain in hospitalized patients]. *Tidsskr Nor Laegeforen* 125(4): 416-418, 2/2005.
18. Holtan A, Kongsgaard UE, Haugen DF. Episodic pain in hospitalized cancer patients. *European Journal of Pain* 10(Supplement 1): S247, 9/2006.

19. Hsu TH, Lu MS, Tsou TS, Lin CC. The relationship of pain, uncertainty, and hope in Taiwanese lung cancer patients. *J Pain Symptom Manage* 26(3): 835-842, 9/2003.
20. Huang HY, Wilkie DJ, Chapman CR, Ting LL. Pain trajectory of Taiwanese with nasopharyngeal carcinoma over the course of radiation therapy. *J Pain Symptom Manage* 25(3): 247-255, 3/2003.
21. Hwang SS, Chang VT, Fairclough DL, Kasimis B. Development of a cancer pain prognostic scale. *J Pain Symptom Manage* 24(4): 366-378, 10/2002.
22. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. *Pain* 101(1-2): 55-64, 1/2003.
23. Kashikar-Zuck S, Keefe FJ, Kornguth P, Beaupre P, Holzberg A, Delong D. Pain coping and the pain experience during mammography: a preliminary study. *Pain* 73(2): 165-172, 11/1997.
24. Klepstad P, Borchgrevink PC, Dale O, Zahlsen K, Aamo T, Fayers P, Fougner B, Kaasa S. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. *Palliat Med* 17(8): 679-687, 12/2003.
25. Konski A, DeSilvio M, Hartsell W, Watkins-Bruner D, Coyne J, Scarantino C, JanJan N. Continuing evidence for poorer treatment outcomes for single male patients: Retreatment data from RTOG 97-14. *Int J Radiat Oncol Biol Phys* 66(1): 229-233, 9/2006.
26. Lai YH, Guo SL, Keefe FJ, Tsai SL, Chien CC, Sung YC, Chen ML. Effects of brief pain education on hospitalized cancer patients with moderate to severe pain. *Support Care Cancer* 12(9): 645-652, 9/2004.
27. Leppert W. Controlled release dihydrocodeine and tramadol in cancer pain treatment-Polish experience. *Eur J Pain* 10(Supplement 1): S147, 9/2006.

28. Liang SY, Yates P, Edwards H, Tsay SL. Factors influencing opioid-taking self-efficacy and analgesic adherence in Taiwanese outpatients with cancer. *Psychooncology*, 3/2008.
29. Lin CC. Comparison of the effects of perceived self-efficacy on coping with chronic cancer pain and coping with chronic low back pain. *Clin J Pain* 14(4): 303-310, 12/1998.
30. Lin CC, Wang P, Lai YL, Lin CL, Tsai SL, Chen TT. Identifying attitudinal barriers to family management of cancer pain in palliative care in Taiwan. *Palliat Med* 14(6): 463-470, 11/2000.
31. Lin CC. Barriers to the analgesic management of cancer pain: a comparison of attitudes of Taiwanese patients and their family caregivers. *Pain* 88(1): 7-14, 10/2000.
32. Lin CC. Congruity of cancer pain perceptions between Taiwanese patients and family caregivers: relationship to patients' concerns about reporting pain and using analgesics. *J Pain Symptom Manage* 21(1): 18-26, 1/2001.
33. Lin CC, Lai YL, Ward SE. Effect of cancer pain on performance status, mood states, and level of hope among Taiwanese cancer patients. *J Pain Symptom Manage* 25(1): 29-37, 1/2003.
34. Lin JT, Mathew P. Cancer pain management in prisons: a survey of primary care practitioners and inmates. *J Pain Symptom Manage* 29(5): 466-473, 5/2005.
35. Long HJ, III, Monk BJ, Huang HQ, Grendys EC, Jr., McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. *Gynecol Oncol* 100(3): 537-543, 3/2006.
36. Lundorff L, Peuckmann V, Sjogren P. Pain management of opioid-treated cancer patients in hospital settings in Denmark. *Acta Anaesthesiol Scand* 52(1): 137-142, 1/2008.
37. Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turiziani A, Speranza R, Tassinari D, Magnani P, Saccani D, Montanari L, Roudnas B, Amadori D, Fabbri L, Nanni O, Raulli P, Poggi B, Fochessati F, Giannunzio D, Barbagallo ML, Minnotti V, Betti M, Giordani S, Piazza E, Scapaticci R, Ferrario S. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. *Support Care Cancer* 13(11): 888-894, 11/2005.
38. McMillan SC, Tittle M, Hagan S, Laughlin J. Management of pain and pain-related symptoms in hospitalized veterans with cancer. *Cancer Nurs* 23(5): 327-336, 10/2000.
39. McMillan SC, Toftagen C, Morgan MA. Relationships among pain, sleep disturbances, and depressive symptoms in outpatients from a comprehensive cancer center. *Oncol Nurs Forum* 35(4): 603-611, 7/2008.
40. McQuellon RP, Thaler HT, Cella D, Moore DH. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. *Gynecol Oncol* 101(2): 296-304, 5/2006.
41. McQuellon RP, Danhauer SC, Russell GB, Shen P, Fenstermaker J, Stewart JH, Levine EA. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. *Ann Surg Oncol* 14(3): 1105-1113, 3/2007.
42. Meghani SH, Keane A. Preference for analgesic treatment for cancer pain among African Americans. *J Pain Symptom Manage* 34(2): 136-147, 8/2007.
43. Monk BJ, Huang HQ, Cella D, Long HJ, III. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. *J Clin Oncol* 23(21): 4617-4625, 7/2005.
44. Mystakidou K, Parpa E, Tsilika E, Mavromati A, Smyrniotis V, Georgaki S, Vlahos L. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. *J Pain* 4(6): 298-306, 8/2003.
45. Mystakidou K, Tsilika E, Parpa E, Kouloulis V, Kouvaris I, Georgaki S, Vlahos L. Long-term cancer pain management in

morphine pre-treated and opioid naive patients with transdermal fentanyl. *Int J Cancer* 107(3): 486-492, 11/2003.

46. Mystakidou K, Parpa E, Katsouda E, Galanos A, Vlahos L. Influence of pain and quality of life on desire for hastened death in patients with advanced cancer. *Int J Palliat Nurs* 10(10): 476-483, 10/2004.
47. Mystakidou K, Parpa E, Tsilika E, Katsouda E, Kouloulis V, Kouvaris J, Georgaki S, Vlahos L. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. *J Pain* 5(2): 119-132, 3/2004.
48. Mystakidou K, Rosenfeld B, Parpa E, Katsouda E, Tsilika E, Galanos A, Vlahos L. Desire for death near the end of life: the role of depression, anxiety and pain. *Gen Hosp Psychiatry* 27(4): 258-262, 7/2005.
49. Mystakidou K, Tsilika E, Parpa E, Katsouda E, Galanos A, Vlahos L. Psychological distress of patients with advanced cancer: influence and contribution of pain severity and pain interference. *Cancer Nurs* 29(5): 400-405, 9/2006.
50. Mystakidou K, Parpa E, Tsilika E, Pathiaki M, Patiraki E, Galanos A, Vlahos L. Sleep quality in advanced cancer patients. *J Psychosom Res* 62(5): 527-533, 5/2007.
51. Nie J, Liu S, Di L. [Cancer pain and its influence on cancer patients' quality of life]. *Zhonghua Zhong Liu Za Zhi* 22(5): 432-434, 9/2000.
52. O'Mahony S, Goulet J, Kornblith A, Abbatiello G, Clarke B, Kless-Siegel S, Breitbart W, Payne R. Desire for hastened death, cancer pain and depression: report of a longitudinal observational study. *J Pain Symptom Manage* 29(5): 446-457, 5/2005.
53. Owen JE, Klapow JC, Casebeer L. Evaluating the relationship between pain presentation and health-related quality of life in outpatients with metastatic or recurrent neoplastic disease. *Qual Life Res* 9(7): 855-863, 2000.
54. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE,

Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Jr., Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. *N Engl J Med* 352(22): 2271-2284, 6/2005.

55. Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT, Jr., Dornseif BE, Damask MC. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. *J Pain Symptom Manage* 23(5): 355-368, 5/2002.
56. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. *J Clin Oncol* 16(4): 1588-1593, 4/1998.
57. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. *Pain* 81(1-2): 129-134, 5/1999.
58. Poulos AR, Gertz MA, Pankratz VS, Post-White J. Pain, mood disturbance, and quality of life in patients with multiple myeloma. *Oncol Nurs Forum* 28(7): 1163-1171, 8/2001.
59. Reyes-Gibby CC, Ba DN, Phi YN, Hoai NN, Van TT, Guo H, Bhat S, Cleeland C. Status of cancer pain in Hanoi, Vietnam: A hospital-wide survey in a tertiary cancer treatment center. *J Pain Symptom Manage* 31(5): 431-439, 5/2006.
60. Rodin G, Zimmermann C, Rydall A, Jones J, Shepherd FA, Moore M, Fruh M, Donner A, Gagliese L. The desire for hastened death in patients with metastatic cancer. *J Pain Symptom Manage* 33(6): 661-675, 6/2007.
61. Sandblom G, Carlsson P, Sigsjö P, Varenhorst E. Pain and health-related quality of life in a geographically defined

- population of men with prostate cancer. *Br J Cancer* 85(4): 497-503, 8/2001.
62. Sandblom G, Carlsson P, Sennfalt K, Varenhorst E. A population-based study of pain and quality of life during the year before death in men with prostate cancer. *Br J Cancer* 90(6): 1163-1168, 3/2004.
 63. Seidman AD, Portenoy R, Yao TJ, Lepore J, Mont EK, Kortmansky J, Onetto N, Ren L, Grechko J, Beltangady M. . Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. *J Natl Cancer Inst* 87(17): 1316-1322, 9/1995.
 64. Sherman AC, Coleman EA, Griffith K, Simonton S, Hine RJ, Cromer J, Latif U, Farley H, Garcia R, Anaissie EJ. Use of a supportive care team for screening and preemptive intervention among multiple myeloma patients receiving stem cell transplantation. *Support Care Cancer* 11(9): 568-574, 9/2003.
 65. Shvartzman P, Friger M, Shani A, Barak F, Yoram C, Singer Y. Pain control in ambulatory cancer patients--can we do better? *J Pain Symptom Manage* 26(2): 716-722, 8/2003.
 66. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. *J Clin Oncol* 21(23): 4277-4284, 12/2003.
 67. Syrjala KL, Abrams JR, Polissar NL, Hansberry J, Robison J, Dupen S, Stillman M, Fredrickson M, Rivkin S, Feldman E, Gralow J, Rieke JW, Raish RJ, Lee DJ, Cleeland CS, Dupen A. Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. *Pain* 135(1-2): 175-186, 3/2008.
 68. Thienthong S, Pratheepawanit N, Limwattananon C, Maoleekoonpaioj S, Lertsanguansinchai P, Chanvej L. Pain and quality of life of cancer patients: a multi-center study in Thailand. *J Med Assoc Thai* 89(8): 1120-1126, 8/2006.
 69. Tsai PS, Chen PL, Lai YL, Lee MB, Lin CC. Effects of electromyography biofeedback-assisted relaxation on pain in patients with advanced cancer in a palliative care unit. *Cancer Nurs* 30(5): 347-353, 9/2007.
 70. Twycross R, Harcourt J, Bergl S. A survey of pain in patients with advanced cancer. *J Pain Symptom Manage* 12(5): 273-282, 11/1996.
 71. Tzeng JI, Chang CC, Chang HJ, Lin CC. Assessing analgesic regimen adherence with the Morisky Medication Adherence Measure for Taiwanese patients with cancer pain. *J Pain Symptom Manage* 36(2): 157-166, 8/2008.
 72. Wallace M, Rauck RL, Moulin D, Thippawong J, Khanna S, Tudor IC. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. *J Int Med Res* 36(2): 343-352, 3/2008.
 73. Wang KY, Ho ST, Ger LP, Wang JJ, Cherng CH, Lin CC. Patient barriers to cancer pain management: from the viewpoint of the cancer patients receiving analgesics in a teaching hospital of Taiwan. *Acta Anaesthesiol Sin* 35(4): 201-208, 12/1997.
 74. Wang RC, Wang SJ, Chang YC, Lin CC. Mood state and quality of sleep in cancer pain patients: a comparison to chronic daily headache. *J Pain Symptom Manage* 33(1): 32-39, 1/2007.
 75. Wells N. Pain intensity and pain interference in hospitalized patients with cancer. *Oncol Nurs Forum* 27(6): 985-991, 7/2000.
 76. Yeo W, Lam KK, Chan AT, Leung TW, Nip SY, Johnson PJ. Transdermal fentanyl for severe cancer-related pain. *Palliat Med* 11(3): 233-239, 5/1997.
 77. Yun YH, Heo DS, Lee IG, Jeong HS, Kim HJ, Kim SY, Kim YH, Ro YJ, Yoon SS, Lee KH, Huh BY. Multicenter study of pain and its management in patients with advanced cancer in Korea. *J Pain Symptom Manage* 25(5): 430-437, 5/2003.

Depressive Disorders

1. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. *J Psychiatr Res* 39(1): 43-53, 1/2005.
2. Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiyah D, Raskin J, Petit C, Derynttenaere K. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: A Randomized controlled trial. *Journal of Clinical Psychiatry* 68(11): 1707-1716, 11/2007.
3. Coats TL, Borenstein DG, Nangia NK, Brown MT. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. *Clin Ther* 26(8): 1249-1260, 8/2004.
4. Davison SN, Jhangri GS. The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients. *J Pain Symptom Manage* 30(5): 465-473, 11/2005.
5. Friedberg F, Quick J. Alexithymia in chronic fatigue syndrome: associations with momentary, recall, and retrospective measures of somatic complaints and emotions. *Psychosom Med* 69(1): 54-60, 1/2007.
6. Hartman JM, Berger A, Baker K, Bolle J, Handel D, Mannes A, Pereira D, St GD, Sonbolian N, Ronsaville D, Torvik S, Calis KA, Phillips TM, Cizza G. Quality of life and pain in premenopausal women with major depressive disorder: The POWER Study. *Health Qual Life Outcomes* 4(1): 2, 1/2006.
7. O'Mahony S, Goulet J, Kornblith A, Abbatiello G, Clarke B, Kless-Siegel S, Breitbart W, Payne R. Desire for hastened death, cancer pain and depression: report of a longitudinal observational study. *J Pain Symptom Manage* 2005;29:446-457. Passik SD, Kirsh KL, Donaghy KB, Portenoy RK. Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. *Clin J Pain* 22(2): 173-181, 2/2006.

8. Poleshuck EL, Giles DE, Tu X. Pain and depressive symptoms among financially disadvantaged women's health patients. *J Womens Health (Larchmt)* 15(2): 182-193, 3/2006.
9. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric History and Psychologic Adjustment as Risk Factors for Aberrant Drug-related Behavior Among Patients With Chronic Pain. *Clin J Pain* 23(4): 307-315, 5/2007.
10. Williams LS, Jones WJ, Shen J, Robinson RL, Kroenke K. Outcomes of newly referred neurology outpatients with depression and pain. *Neurology* 63(4): 674-677, 8/2004.

Fabry Disease

1. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. *Eur J Clin Invest* 34(12): 838-844, 12/2004.
2. Cleeland CS. Pain assessment: the advantages of using pain scales in lysosomal storage diseases. *Acta Paediatr Suppl* 91(439): 43-47, 2002.
3. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. *J Med Genet* 43(4): 347-352, 4/2006.
4. Hoffmann B, Garcia de LA, Mehta A, Beck M, Widmer U, Ricci R. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). *J Med Genet* 42(3): 247-252, 3/2005.
5. Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, Santus F, Beck M. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. *Acta Paediatr* 96(1): 122-127, 1/2007.
6. Ries M, Mengel E, Kutschke G, Kim KS, Birklein F, Krummenauer F, Beck M. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. *J Inherit Metab Dis* 26(4): 413-414, 2003.

7. Schiffmann R, Kopp JB, Austin HA, III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. *JAMA* 285(21): 2743-2749, 6/2001.

Fibromyalgia

1. Armstrong DG, Chappell AS, Le TK, Kajdasz DK, Backonja M, D'Souza DN, Russell JM. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes. *Pain Med* 8(5): 410-418, 7/2007.
2. Arnold LM, Lu Y, Crofford LJ, Wohleisch M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. *Arthritis Rheum* 50(9): 2974-2984, 9/2004.
3. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. *Pain* 119(1-3): 5-15, 12/2005.
4. Arnold LM, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. *J Womens Health (Larchmt)* 16(8): 1145-1156, 10/2007.
5. Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck PE, Welge JA, Bishop F, Stanford KE, Hess EV, Hudson JI. Gabapentin in the treatment of fibromyalgia - A randomized, double-blind, placebo-controlled, multicenter trial. *Arthritis and Rheumatism* 56(4): 1336-1344, 4/2007.
6. Dungey J, Arnold L, Pritchett Y, Robinson M, D'Souza D, Wernicke J. PR_186: Duloxetine in the Treatment of Fibromyalgia in Women: Results From 2 Clinical Trials. *Archives of Physical Medicine and Rehabilitation* 87(11): e36, 11/2006.
7. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohleisch MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM. Efficacy and

safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. *Pain* 136(3): 432-444, 6/2008.

8. Rutledge DN, Jones CJ. Effects of topical essential oil on exercise volume after a 12-week exercise program for women with fibromyalgia: A pilot study. *Journal of Alternative and Complementary Medicine* 13(10): 1099-1106, 12/2007.

HIV/AIDS

1. Breitbart W, McDonald MV, Rosenfeld B, Passik SD, Hewitt D, Thaler H, Portenoy RK. Pain in ambulatory AIDS patients. I: Pain characteristics and medical correlates. *Pain* 68(2-3): 315-321, 12/1996.
2. Breitbart W, Rosenfeld BD, Passik SD, McDonald MV, Thaler H, Portenoy RK. The undertreatment of pain in ambulatory AIDS patients. *Pain* 65(2-3): 243-249, 5/1996.
3. Breitbart W, Rosenfeld B, Passik S, Kaim M, Funesti-Esch J, Stein K. A comparison of pain report and adequacy of analgesic therapy in ambulatory AIDS patients with and without a history of substance abuse. *Pain* 72(1-2): 235-243, 8/1997.
4. Breitbart W, Passik S, McDonald MV, Rosenfeld B, Smith M, Kaim M, Funesti-Esch J. Patient-related barriers to pain management in ambulatory AIDS patients. *Pain* 76(1-2): 9-16, 5/1998.
5. Griswold GA, Evans S, Spielman L, Fishman B. Coping strategies of HIV patients with peripheral neuropathy. *AIDS Care* 17(6): 711-720, 8/2005.
6. Hoyt MJ, Nokes K, Newshan G, Staats JA, Thorn M. The effect of chemical dependency on pain perception in persons with AIDS. *J Assoc Nurses AIDS Care* 5(3): 33-38, 5/1994.
7. Larue F, Fontaine A, Colleau SM. Underestimation and undertreatment of pain in HIV disease: multicentre study. *BMJ* 314(7073): 23-28, 1/1997.

8. Newshan G, Lefkowitz M. Transdermal fentanyl for chronic pain in AIDS: a pilot study. *J Pain Symptom Manage* 21(1): 69-77, 1/2001.
9. Simmonds MJ, Novy D, Sandoval R. The differential influence of pain and fatigue on physical performance and health status in ambulatory patients with human immunodeficiency virus. *Clin J Pain* 21(3): 200-206, 5/2005.
10. Smith MY, Egert J, Winkel G, Jacobson J. The impact of PTSD on pain experience in persons with HIV/AIDS. *Pain* 98(1-2): 9-17, 7/2002.
11. von Gunten CF, Eappen S, Cleary JF, Taylor SG, Moots P, Regevik N, Cleeland C, Celia D. Flecainide for the treatment of chronic neuropathic pain: A Phase II trial. *Palliat Med* 21(8): 667-672, 2007.

Minority Studies

1. Breitbart W, McDonald MV, Rosenfeld B, Passik SD, Hewitt D, Thaler H, Portenoy RK. Pain in ambulatory AIDS patients. I: Pain characteristics and medical correlates. *Pain* 68(2-3): 315-321, 12/1996.
2. Castel LD, Abernethy AP, Li Y, Depuy V, Saville BR, Hartmann KE. Hazards for pain severity and pain interference with daily living, with exploration of brief pain inventory cutpoints, among women with metastatic breast cancer. *J Pain Symptom Manage* 34(4): 380-392, 10/2007.
3. Castel LD, Saville BR, Depuy V, Godley PA, Hartmann KE, Abernethy AP. Racial differences in pain during 1 year among women with metastatic breast cancer: a hazards analysis of interval-censored data. *Cancer* 112(1): 162-170, 1/2008.
4. Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ. Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. *Ann Intern Med* 127(9): 813-816, 11/1997.
5. Meghani SH, Keane A. Preference for analgesic treatment for cancer pain among African Americans. *J Pain Symptom Manage* 34(2): 136-147, 8/2007.
6. Poleshuck EL, Giles DE, Tu X. Pain and depressive symptoms among financially disadvantaged women's health patients. *J Womens Health (Larchmt)* 15(2): 182-193, 3/2006.

Neuromuscular Pain

1. Abe Y, Miyashita M, Ito N, Shirai Y, Momose Y, Ichikawa Y, Tsuji S, Kazuma K. Attitude of outpatients with neuromuscular diseases in Japan to pain and use of analgesics. *J Neurol Sci* 267(1-2): 22-27, 4/2008.
2. Ang D, Kesavalu R, Lydon JR, Lane KA, Bigatti S. Exercise-based motivational interviewing for female patients with fibromyalgia: a case series. *Clin Rheumatol* 26(11): 1843-1849, 11/2007.
3. Babic-Naglic D. [The diagnostics of chronic musculoskeletal pain]. *Reumatizam* 54(2): 32-36, 2007.
4. Breuer B, Pappagallo M, Knotkova H, Guleyupoglu N, Wallenstein S, Portenoy RK. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. *Clinical Therapeutics* 29(9): 2022-2030, 9/2007.
5. Bryce TN, Norrbrink C, Cardenas DD, Dijkers M, Felix ER, Finnerup NB, Kennedy P, Lundberg T, Richards JS, Rintala DH, Siddall P, Widerstrom-Noga E. From the 2006 NIDRR SCI measures meeting - Pain after spinal cord injury: An evidence-based review for clinical practice and research. *Journal of Spinal Cord Medicine* 30(5): 421-440, 2007.
6. Chae J, Yu DT, Walker ME, Kirsteins A, Elovic EP, Flanagan SR, Harvey RL, Zorowitz RD, Frost FS, Grill JH, Fang ZP. Intramuscular electrical stimulation for hemiplegic shoulder pain: a 12-month follow-up of a multiple-center, randomized clinical trial. *Am J Phys Med Rehabil* 84(11): 832-842, 11/2005.
7. Chae J, Ng A, Yu DT, Kirsteins A, Elovic EP, Flanagan SR, Harvey RL, Zorowitz RD, Fang ZP. Intramuscular electrical stimulation for shoulder pain in hemiplegia: does time from stroke onset predict treatment success? *Neurorehabil Neural Repair* 21(6): 561-567, 11-12/2007.

8. Chae J, Mascarenhas D, Yu DT, Kirsteins A, Elovic EP, Flanagan SR, Harvey RL, Zorowitz RD, Fang ZP. Poststroke shoulder pain: its relationship to motor impairment, activity limitation, and quality of life. *Arch Phys Med Rehabil* 88(3): 298-301, 3/2007.
9. Dalpiaz AS, Dodds TA. Myofascial pain response to topical lidocaine patch therapy: case report. *J Pain Palliat Care Pharmacother* 16(1): 99-104, 2002.
10. Dalpiaz AS, Lordon SP, Lipman AG. Topical lidocaine patch therapy for myofascial pain. *J Pain Palliat Care Pharmacother* 18(3): 15-34, 2004.
11. Damush TM, Wu J, Bair MJ, Sutherland JM, Kroenke K. Self-management practices among primary care patients with musculoskeletal pain and depression. *J Behav Med* 31(4): 301-307, 8/2008.
12. Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. *Clin Neuropharmacol* 30(4): 201-205, 7/2007.
13. Ehde DM, Osborne TL, Hanley MA, Jensen MP, Kraft GH. The scope and nature of pain in persons with multiple sclerosis. *Mult Scler* 12(5): 629-638, 10/2006.
14. Guy-Coichard C, Nguyen DT, Delorme T, Boureau F. Pain in hereditary neuromuscular disorders and myasthenia gravis: a national survey of frequency, characteristics, and impact. *J Pain Symptom Manage* 35(1): 40-50, 1/2008.
15. Harris JE, Eng JJ. Individuals with the dominant hand affected following stroke demonstrate less impairment than those with the nondominant hand affected. *Neurorehabil Neural Repair* 20(3): 380-389, 9/2006.
16. Harris JE, Eng JJ. Paretic upper-limb strength best explains arm activity in people with stroke. *Physical Therapy* 87(1): 88-97, 1/2007.
17. Iolascon G, Gimigliano F, Gimigliano R. PR_279: Pain in Stroke Survivors: Epidemiology and Impact on Functional Outcome. *Archives of Physical Medicine and Rehabilitation* 87(11): e51, 11/2006.
18. Jensen MP, Hoffman AJ, Cardenas DD. Chronic pain in individuals with spinal cord injury: a survey and longitudinal study. *Spinal Cord* 43(12): 704-712, 12/2005.
19. Jensen MP, Abresch RT, Carter GT, McDonald CM. Chronic pain in persons with neuromuscular disease. *Arch Phys Med Rehabil* 86(6): 1155-1163, 6/2005.
20. Kong KH, Woon VC, Yang SY. Prevalence of chronic pain and its impact on health-related quality of life in stroke survivors. *Arch Phys Med Rehabil* 85(1): 35-40, 1/2004.
21. Lang E, Eisele R, Jankowsky H, Kastner S, Liebig K, Martus P, Neundorfer B. [Outcome quality of treatment for chronic low back pain under primary care conditions]. *Schmerz* 14(3): 146-159, 6/2000.
22. Lang E, Liebig K, Kastner S, Neundorfer B, Heuschmann P. Multidisciplinary rehabilitation versus usual care for chronic low back pain in the community: effects on quality of life. *Spine J* 3(4): 270-276, 7/2003.
23. Lee MA, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson's disease. *J Pain Symptom Manage* 32(5): 462-469, 11/2006.
24. Nalamachu S, Crockett RS, Gammaitoni AR, Gould EM. A Comparison of the Lidocaine Patch 5% vs Naproxen 500 mg Twice Daily for the Relief of Pain Associated With Carpal Tunnel Syndrome: A 6-Week, Randomized, Parallel-Group Study. *MedGenMed* 8(3): 33, 2006.
25. Nalamachu S, Crockett RS, Mathur D. Lidocaine patch 5 for carpal tunnel syndrome: how it compares with injections: a pilot study. *J Fam Pract* 55(3): 209-214, 3/2006.
26. Osborne TL, Raichle KA, Jensen MP, Ehde DM, Kraft G. The reliability and validity of pain interference measures in persons with multiple sclerosis. *J Pain Symptom Manage* 32(3): 217-229, 9/2006.
27. Raichle KA, Osborne TL, Jensen MP, Cardenas D. The reliability and validity of pain interference measures in persons with spinal cord injury. *J Pain* 7(3): 179-186, 3/2006.

28. Renzenbrink GJ, IJzerman MJ. Percutaneous neuromuscular electrical stimulation (P-NMES) for treating shoulder pain in chronic hemiplegia. Effects on shoulder pain and quality of life. *Clin Rehabil* 18(4): 359-365, 6/2004.
29. Sawatzky BJ, Slobogean GP, Reilly CW, Chambers CT, Hol AT. Prevalence of shoulder pain in adult- versus childhood-onset wheelchair users: a pilot study. *J Rehabil Res Dev* 42(3 Suppl 1): 1-8, 5/2005.
30. Sculco AD, Paup DC, Fernhall B, Sculco MJ. Effects of aerobic exercise on low back pain patients in treatment. *Spine J* 1(2): 95-101, 3/2001.
31. Shah RR, Haghighpanah S, Elovic EP, Flanagan SR, Behnegar A, Nguyen V, Page SJ, Fang ZP, Chae J. MRI Findings in the Painful Poststroke Shoulder. *Stroke* 39(6): 1808-1813, 6/2008.
32. Tyler EJ, Jensen MP, Engel JM, Schwartz L. The reliability and validity of pain interference measures in persons with cerebral palsy. *Arch Phys Med Rehabil* 83(2): 236-239, 2/2002.
33. Wallace M, Rauck RL, Moulin D, Thippawong J, Khanna S, Tudor IC. Once-daily OROS((R)) hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study. *Int J Clin Pract* 61(10): 1671-1676, 10/2007.
34. Wallace M, Skowronski R, Khanna S, Tudor IC, Thippawong J. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). *Curr Med Res Opin* 23(5): 981-989, 5/2007.
35. Yu DT, Chae J, Walker ME, Fang ZP. Percutaneous intramuscular neuromuscular electric stimulation for the treatment of shoulder subluxation and pain in patients with chronic hemiplegia: a pilot study. *Arch Phys Med Rehabil* 82(1): 20-25, 1/2001.
36. Yu DT, Chae J, Walker ME, Kirsteins A, Elovic EP, Flanagan SR, Harvey RL, Zorowitz RD, Frost FS, Grill JH, Feldstein M, Fang ZP. Intramuscular neuromuscular electric stimulation for poststroke

shoulder pain: a multicenter randomized clinical trial. *Arch Phys Med Rehabil* 85(5): 695-704, 5/2004.

Neuropathic Pain

1. Backonja MM, Stacey B. Neuropathic pain symptoms relative to overall pain rating. *J Pain* 5(9): 491-497, 11/2004.
2. Clermont-Gnamien S, Atlani S, Attal N, Le MF, Guirimand F, Brasseur L. [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain]. *Presse Med* 31(39 Pt 1): 1840-1845, 11/2002.
3. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. *J Pain* 5(6): 344-356, 8/2004.
4. Erdemoglu AK, Varlibas A. Effectiveness of oxcarbazepine in symptomatic treatment of painful diabetic neuropathy. *Neurol India* 54(2): 173-177, 6/2006.
5. Freynhagen R, Grond S, Schupfer G, Hagebeuker A, Schmelz M, Ziegler D, Von Giesen HJ, Junker U, Wagner KJ, Konrad C. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. *International Journal of Clinical Practice* 61(12): 1989-1996, 12/2007.
6. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. *J Pain Symptom Manage* 30(4): 374-385, 10/2005.
7. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. *J Pain* 7(12): 892-900, 12/2006.
8. Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley K, A'hern R. A phase II study to establish the efficacy and toxicity of sodium

- valproate in patients with cancer-related neuropathic pain. *J Pain Symptom Manage* 21(3): 204-209, 3/2001.
9. Katz NP, Gammaitoni AR, Davis MW, Dworkin RH. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. *Pain Med* 3(4): 324-332, 12/2002.
 10. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. *Eur J Pain* 10(2): 127-135, 2/2006.
 11. Patarica Huber E, Pjevic M. 526 Therapy related neuropathic pain in breast cancer patients and its treatment. *European Journal of Pain* 10(Supplement 1): S139, 9/2006.
 12. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. *Pain Med* 7(5): 373-385, 9/2006.
 13. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. *Clin J Pain* 23(6): 490-496, 7/2007.
 14. Semenchuk MR, Sherman S. Effectiveness of tizanidine in neuropathic pain: an open-label study. *J Pain* 1(4): 285-292, 2000.
 15. Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. *J Diabetes Complications* 20(1): 26-33, 1/2006.
 16. Tolle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. *Pain Pract* 6(3): 153-160, 9/2006.
 17. von Gunten CF, Eappen S, Cleary JF, Taylor SG, Moots P, Regevik N, Cleeland C, Celia D. Flecainide for the treatment of chronic neuropathic pain: A Phase II trial. *Palliative Medicine* 21(8): 667-672, 2007.

18. Wardell DW, Rintala DH, Duan Z, Tan G. A pilot study of healing touch and progressive relaxation for chronic neuropathic pain in persons with spinal cord injury. *J Holist Nurs* 24(4): 231-240, 12/2006.
19. White S. Assessment of chronic neuropathic pain and the use of pain tools. *Br J Nurs* 13(7): 372-378, 4/2004.
20. White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. *Pain Med* 4(4): 321-330, 12/2003.
21. Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S. Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France. *Curr Med Res Opin* 23(9): 2035-2042, 9/2007.
22. Zakrzewska JM, Lopez BC, Kim SE, Varian EA, Coakham HB. Patient satisfaction after surgery for trigeminal neuralgia - development of a questionnaire. *Acta Neurochir (Wien)* 147(9): 925-932, 9/2005.

Osteoarthritis and Other Joint Diseases

1. Measuring quality of life in women with osteoporosis. Osteoporosis Quality of Life Study Group. *Osteoporos Int* 7(5): 478-487, 1997.
2. Brinker MR, O'connor DP. Outcomes of tibial nonunion in older adults following treatment using the Ilizarov method. *J Orthop Trauma* 21(9): 634-642, 10/2007.
3. Brinker MR, O'connor DP, Crouch CC, Mehlhoff TL, Bennett JB. Ilizarov Treatment of Infected Nonunions of the Distal Humerus After Failure of Internal Fixation: An Outcomes Study. *J Orthop Trauma* 21(3): 178-184, 3/2007.
4. Coats TL, Borenstein DG, Nangia NK, Brown MT. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. *Clin Ther* 26(8): 1249-1260, 8/2004.

5. Cowan DT, Wilson-Barnett J, Griffiths P, Vaughan DJ, Gondhia A, Allan LG. A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. *Pain Med* 6(2): 113-121, 3/2005.
6. Galer BS, Sheldon E, Patel N, Coddling C, Burch F, Gammaitoni AR. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. *Curr Med Res Opin* 20(9): 1455-1458, 9/2004.
7. Gammaitoni AR, Galer BS, Lacouture P, Domingos J, Schlagheck T. Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. *Pain Med* 4(1): 21-30, 3/2003.
8. Gerber L, el-Gabalawy H, Arayssi T, Furst G, Yarboro C, Schumacher HR. Polyarticular arthritis, independent of rheumatoid factor, is associated with poor functional outcome in recent onset inflammatory synovitis. *Journal of Back and Musculoskeletal Rehabilitation* 14(3): 105-109, 2000.
9. Gerber LH, Furst G, Yarboro C, el-Gabalawy H. Number of active joints, not diagnosis, is the primary determinant of function and performance in early synovitis. *Clin Exp Rheumatol* 21(5 Suppl 31): S65-S70, 9/2003.
10. Gimbel J, Linn R, Hale M, Nicholson B. Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study. *Am J Ther* 12(4): 311-319, 7/2005.
11. Gorodetskyi IG, Gorodnichenko AI, Tursin PS, Reshetnyak VK, Uskov ON. Non-invasive interactive neurostimulation in the post-operative recovery of patients with a trochanteric fracture of the femur. *Journal of Bone and Joint Surgery-British Volume* 89B(11): 1488-1494, 11/2007.
12. Gould E, Ma T. Back pain. *Archives of Physical Medicine and Rehabilitation* 87(11): e38, 11/2006.
13. Kapstad H, Hanestad BR, Langeland N, Rustoen T, Stavem K. Cutpoints for mild, moderate and severe pain in patients with osteoarthritis of the hip or knee ready for joint replacement surgery. *BMC Musculoskelet Disord* 9(1): 55, 4/2008.
14. Kelly MH, Brillante B, Collins MT. Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions. *Osteoporos Int* 19(1): 57-63, 1/2008.
15. Kelly MH, Brillante B, Collins MT. Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions. *Osteoporos Int* 19(1): 57-63, 1/2008.
16. Markenson JA, Croft J, Zhang PG, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. *Clin J Pain* 21(6): 524-535, 11/2005.
17. McDonald C, Wilson M, Todd J. 686 Butrans (Buprenorphine) Transdermal Patches Improve Quality of Life in patients with Osteoarthritis(OA). *European Journal of Pain* 10(Supplement 1): S179, 9/2006.
18. Mystakidou K, Parpa E, Tsilika E, Mavromati A, Smyrniotis V, Georgaki S, Vlahos L. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. *J Pain* 4(6): 298-306, 8/2003.
19. Pavelka K, Le L, X, Bjorneboe O, Herrero-Beaumont G, Richarz U. Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. *Curr Med Res Opin* 20(12): 1967-1977, 12/2004.
20. Portenoy RK, Farrar JT, Backonja MM, Cleeland CS, Yang K, Friedman M, Colucci SV, Richards P. Long-term Use of Controlled-release Oxycodone for Noncancer Pain: Results of a 3-year Registry Study. *Clin J Pain* 23(4): 287-299, 5/2007.
21. Rosenthal M, Moore P, Groves E, Iwan T, Schlosser LG, Dziewanowska Z, Negro-Vilar A. Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA):

findings from a pilot study. *J Opioid Manag* 3(3): 145-154, 5/2007.

22. Thie NM, Prasad NG, Major PW. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. *J Rheumatol* 28(6): 1347-1355, 6/2001.
23. Williams, V.S.; Smith, M.Y.; Fehnel, S.E. The validity and utility of the BPI interference measures for evaluating the impact of osteoarthritic pain. *J Pain Symptom Manage* 31(1): 48-57, 1/2006.

Psychosocial Studies

1. Babic-Naglic D. [The diagnostics of chronic musculoskeletal pain]. *Reumatizam* 54(2): 32-36, 2007.
2. Ehde DM, Osborne TL, Hanley MA, Jensen MP, Kraft GH. The scope and nature of pain in persons with multiple sclerosis. *Mult Scler* 12(5): 629-638, 10/2006.
3. Ersek M, Turner JA, Cain KC, Kemp CA. Chronic pain self-management for older adults: a randomized controlled trial [ISRCTN11899548]. *BMC Geriatr* 4: 7, 7/2004.
4. Jensen MP, Keefe FJ, Lefebvre JC, Romano JM, Turner JA. One- and two-item measures of pain beliefs and coping strategies. *Pain* 104(3): 453-469, 8/2003.
5. Karasz A, Zallman L, Berg K, Gourevitch M, Selwyn P, Arnsten JH. The experience of chronic severe pain in patients undergoing methadone maintenance treatment. *J Pain Symptom Manage* 28(5): 517-525, 11/2004.
6. Poleshuck EL, Giles DE, Tu X. Pain and depressive symptoms among financially disadvantaged women's health patients. *J Womens Health (Larchmt)* 15(2): 182-193, 3/2006.
7. Rodin G, Zimmermann C, Rydall A, Jones J, Shepherd FA, Moore M, Fruh M, Donner A, Gagliese L. The desire for hastened death in patients with metastatic cancer. *J Pain Symptom Manage* 33(6): 661-675, 6/2007.

8. Sherman AC, Coleman EA, Griffith K, Simonton S, Hine RJ, Cromer J, Latif U, Farley H, Garcia R, Anaissie EJ. Use of a supportive care team for screening and preemptive intervention among multiple myeloma patients receiving stem cell transplantation. *Support Care Cancer* 11(9): 568-574, 9/2003.
9. Stroud MW, Turner JA, Jensen MP, Cardenas DD. Partner responses to pain behaviors are associated with depression and activity interference among persons with chronic pain and spinal cord injury. *J Pain* 7(2): 91-99, 2/2006.
10. Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric History and Psychologic Adjustment as Risk Factors for Aberrant Drug-related Behavior Among Patients With Chronic Pain. *Clin J Pain* 23(4): 307-315, 5/2007.

Surgical and Procedural Pain

1. Beauregard L, Pomp A, Choiniere M. Severity and impact of pain after day-surgery. *Can J Anaesth* 45(4): 304-311, 4/1998.
2. Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Wong GY, Sloan JA, Novotny PJ, Lewis BD, Welch TJ, Farrell MA, Maus TP, Lee RA, Reading CC, Petersen IA, Pickett DD. Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. *Radiology* 224(1): 87-97, 7/2002.
3. Chelly JE, Nissen CW, Rodgers AJ, Smugar SS, Tershakovec AM. The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic pain. *Curr Med Res Opin* 23(1): 195-206, 1/2007.
4. Coleman KL, Boone DA, Laing LS, Mathews DE, Smith DG. Quantification of prosthetic outcomes: Elastomeric gel liner with locking pin suspension versus polyethylene foam liner with neoprene sleeve suspension. *J Rehabil Res Dev* 41(4): 591-602, 7/2004.

5. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. *Am J Kidney Dis* 42(6): 1239-1247, 12/2003.
6. Dell DD, Weaver C, Kozempel J, Barsevick A. Recovery after transverse rectus abdominis myocutaneous flap breast reconstruction surgery. *Oncol Nurs Forum* 35(2): 189-196, 3/2008.
7. Girard F, Chouinard P, Boudreault D, Poirier C, Richard C, Ruel M, Ferraro P. Prevalence and impact of pain on the quality of life of lung transplant recipients: a prospective observational study. *Chest* 130(5): 1535-1540, 11/2006.
8. Kaplan M, Miliman A, Drummond P. PR_196: Treatment of Chronic Nonmalignant Pain With Polymer-Coated Extended-Release Morphine Sulfate Capsules in Patients Transitioned From Other Sustained-Release Opioids. *Arch Phys Med Rehabil* 87(11): e38, 11/2006.
9. Kushner DM, LaGalbo R, Connor JP, Chappell R, Stewart SL, Hartenbach EM. Use of a bupivacaine continuous wound infusion system in gynecologic oncology: a randomized trial. *Obstet Gynecol* 106(2): 227-233, 8/2005.
10. Lin LY, Wang RH. Abdominal surgery, pain and anxiety: preoperative nursing intervention. *J Adv Nurs* 51(3): 252-260, 8/2005.
11. Locklin JK, Mannes A, Berger A, Wood BJ. Palliation of soft tissue cancer pain with radiofrequency ablation. *J Support Oncol* 2(5): 439-445, 9/2004.
12. Mendoza TR, Chen C, Brugger A, Hubbard R, Snabes M, Palmer SN, Zhang Q, Cleeland CS. The utility and validity of the modified brief pain inventory in a multiple-dose postoperative analgesic trial. *Clin J Pain* 20(5): 357-362, 9/2004.
13. Mendoza TR, Chen C, Brugger A, Hubbard R, Snabes M, Palmer SN, Zhang Q, Cleeland CS. Lessons learned from a multiple-dose post-operative analgesic trial. *Pain* 109(1-2): 103-109, 5/2004.
14. Mitchell AC, Fallon MT. A single infusion of intravenous ketamine improves pain relief in patients with critical limb ischaemia: results of a double blind randomised controlled trial. *Pain* 97(3): 275-281, 6/2002.
15. Ochroch EA, Gottschalk A, Augoustides JG, Aukburg SJ, Kaiser LR, Shrager JB. Pain and physical function are similar following axillary, muscle-sparing vs posterolateral thoracotomy. *Chest* 128(4): 2664-2670, 10/2005.
16. Ochroch EA, Gottschalk A, Troxel AB, Farrar JT. Women suffer more short and long-term pain than men after major thoracotomy. *Clin J Pain* 22(5): 491-498, 6/2006.
17. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, Hubbard RC, Hsu PH, Saidman LJ, Mangano DT. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. *J Thorac Cardiovasc Surg* 125(6): 1481-1492, 6/2003.
18. Passard A, Attal N, Benadhira R, Brasseur L, Saba G, Sichere P, Perrot S, Januel D, Bouhassira D. Effects of unilateral repetitive transcranial magnetic stimulation of the motor cortex on chronic widespread pain in fibromyalgia. *Brain* 130(Pt 10): 2661-2670, 10/2007.
19. Ponsford J, Hill B, Karamitsios M, Bahar-Fuchs A. Factors influencing outcome after orthopedic trauma. *J Trauma* 64(4): 1001-1009, 4/2008.
20. Schoedinger GR, III, Hildebolt CF, Kumar A. A short pain survey for postoperative assessment of spine patients in a nonacademic setting. *J Surg Orthop Adv* 13(4): 199-205, 2004.
21. Soulez G, Therasse E, Monfared AA, Blair JF, Choiniere M, Elkouri S, Beaudoin N, Giroux MF, Cliche A, Leloirier J, Oliva VL. Pain and quality of life assessment after endovascular versus open repair of abdominal aortic aneurysms in patients at low risk. *J Vasc Interv Radiol* 16(8): 1093-1100, 8/2005.
22. Su L, Tucker R, Frey SE, Gress JO, Chan IS, Kuter BJ, Guess HA. Measuring injection-site pain associated with vaccine administration in adults: a randomised, double-blind,

placebo-controlled clinical trial. *J Epidemiol Biostat* 5(6): 359-365, 2000.

23. Tittle MB, McMillan SC, Hagan S. Validating the brief pain inventory for use with surgical patients with cancer. *Oncol Nurs Forum* 30(2): 325-330, 3/2003.
24. Van Tongeren RB, Hamming JF, Fibbe WE, Van W, V, Frerichs SJ, Stiggelbout AM, Van Bockel JH, Lindeman JH. Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. *J Cardiovasc Surg (Torino)* 49(1): 51-58, 2/2008.
25. Vickers AJ, Rusch VW, Malhotra VT, Downey RJ, Cassileth BR. Acupuncture is a feasible treatment for post-thoracotomy pain: results of a prospective pilot trial. *BMC Anesthesiol* 6: 5, 2006.
26. Vo PG, Marx S, Best AE, Lockhart E. Systematic overview of the psychometric properties of the brief pain inventory in malignant and non-malignant pain. *Value in Health* 10(3): A176, Abbott Labs, Abbott Pk, IL 60064 USA, 5/2007.
27. Zalon ML. Comparison of pain measures in surgical patients. *J Nurs Meas* 7(2): 135-152, 1999.
28. Zalon ML. Correlates of recovery among older adults after major abdominal surgery. *Nurs Res* 53(2): 99-106, 3/2004.

Validation Studies

1. Aisyaturridha A, Naing L, Nizar AJ. Validation of the Malay Brief Pain Inventory questionnaire to measure cancer pain. *J Pain Symptom Manage* 31(1): 13-21, 1/2006.
2. Badia X, Muriel C, Gracia A, Nunez-Olarte JM, Perulero N, Galvez R, Carulla J, Cleeland CS. [Validation of the Spanish version of the Brief Pain Inventory in patients with oncological pain]. *Med Clin (Barc)* 120(2): 52-59, 1/2003.
3. Bonezzi C, Nava A, Barbieri M, Bettaglio R, Demartini L, Miotti D, Paulin L. [Validazione della versione italiana del Brief Pain

Inventory nei pazienti con dolore cronico]. *Minerva Anesthesiol* 68(7-8): 607-611, 7/2002.

4. Breitbart W, Rosenfeld B, Passik S, Kaim M, Funesti-Esch J, Stein K. A comparison of pain report and adequacy of analgesic therapy in ambulatory AIDS patients with and without a history of substance abuse. *Pain* 72(1-2): 235-243, 8/1997.
5. Breuer B, Pappagallo M, Knotkova H, Guleyupoglu N, Wallenstein S, Portenoy RK. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. *Clinical Therapeutics* 29(9): 2022-2030, 9/2007.
6. Bryce TN, Norrbrink C, Cardenas DD, Dijkers M, Felix ER, Finnerup NB, Kennedy P, Lundberg T, Richards JS, Rintala DH, Siddall P, Widerstrom-Noga E. From the 2006 NIDRR SCI measures meeting - Pain after spinal cord injury: An evidence-based review for clinical practice and research. *Journal of Spinal Cord Medicine* 30(5): 421-440, 2007.
7. Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, de CF. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. *J Pain Symptom Manage* 23(3): 239-255, 3/2002.
8. Caraceni A, Mendoza TR, Menciaaglia E, Barattella C, Edwards K, Forjaz MJ, Martini C, Serlin RC, de CF, Cleeland CS. A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). *Pain* 65(1): 87-92, 4/1996.
9. Caraceni A. Evaluation and assessment of cancer pain and cancer pain treatment. *Acta Anaesthesiol Scand* 45(9): 1067-1075, 10/2001.
10. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. *Cancer* 88(9): 2164-2171, 5/2000.
11. Clark K, Greaves J, Sung E, Glare P. Development and introduction of a pain score documentation chart in the

acute oncology setting. *Asia-Pacific Journal of Clinical Oncology* 3(2): 89-94, 6/2007.

12. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singapore* 23(2): 129-138, 3/1994.
13. Cleeland CS. Pain assessment: the advantages of using pain scales in lysosomal storage diseases. *Acta Paediatr Suppl* 91(439): 43-47, 2002.
14. Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient's experience. *Clin Cancer Res* 12(20 Pt 2): 6236s-6242s, 10/2006.
15. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. *J Pain* 5(6): 344-356, 8/2004.
16. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. *Pain* 17(2): 197-210, 10/1983.
17. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von ST, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain* 9(2): 105-121, 2/2008.
18. Ersek M, Turner JA, Kemp CA. Use of the chronic pain coping inventory to assess older adults' pain coping strategies. *J Pain* 7(11): 833-842, 11/2006.
19. Ewing G, Todd C, Rogers M, Barclay S, McCabe J, Martin A. Validation of a symptom measure suitable for use among

palliative care patients in the community: CAMPAS-R. *J Pain Symptom Manage* 27(4): 287-299, 4/2004.

20. Franneby U, Gunnarsson U, Andersson M, Heuman R, Nordin P, Nyren O, Sandblom G. Validation of an Inguinal Pain Questionnaire for assessment of chronic pain after groin hernia repair. *Br J Surg* 95(4): 488-493, 4/2008.
21. Freynhagen R, Grond S, Schupfer G, Hagebeuker A, Schmelz M, Ziegler D, Von Giesen HJ, Junker U, Wagner KJ, Konrad C. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. *International Journal of Clinical Practice* 61(12): 1989-1996, 12/2007.
22. Galer BS, Henderson J, Perander J, Jensen MP. Course of symptoms and quality of life measurement in Complex Regional Pain Syndrome: a pilot survey. *J Pain Symptom Manage* 20(4): 286-292, 10/2000.
23. Ger LP, Ho ST, Sun WZ, Wang MS, Cleeland CS. Validation of the Brief Pain Inventory in a Taiwanese population. *J Pain Symptom Manage* 18(5): 316-322, 11/1999.
24. Gjeilo KH, Stenseth R, Wahba A, Lydersen S, Klepstad P. Validation of the Brief Pain Inventory in Patients Six Months After Cardiac Surgery. *J Pain Symptom Manage*, 7/2007.
25. Gunnarsdottir S, Serlin RC, Ward S. Patient-related barriers to pain management: the Icelandic Barriers Questionnaire II. *J Pain Symptom Manage* 29(3): 273-285, 3/2005.
26. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. *J Clin Oncol* 26(15): 2544-2549, 5/2008.
27. Haris K, Li K, Flynn C, Chow E. Worst, average or current pain in the brief pain inventory: Which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? *Clinical Oncology* 19(7): 523-527, 9/2007.
28. Holen JC, Hjermstad MJ, Loge JH, Fayers PM, Caraceni A, de CF, Forbes K, Furst CJ, Radbruch L, Kaasa S. Pain Assessment

Tools: Is the Content Appropriate for Use in Palliative Care? *J Pain Symptom Manage* 32(6): 567-580, 12/2006.

29. Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz H, Lenzi R, Theriault R, Martin C, Yasko A. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. *J Pain Symptom Manage* 16(3): 171-178, 9/1998.
30. Jensen MP, Keefe FJ, Lefebvre JC, Romano JM, Turner JA. One- and two-item measures of pain beliefs and coping strategies. *Pain* 104(3): 453-469, 8/2003.
31. Kalyadina SA, Ionova TI, Ivanova MO, Uspenskaya OS, Kishitovich AV, Mendoza TR, Guo H, Novik A, Cleeland CS, Wang XS. Russian Brief Pain Inventory: validation and application in cancer pain. *J Pain Symptom Manage* 35(1): 95-102, 1/2008.
32. Kapstad H, Hanestad BR, Langeland N, Rustoen T, Stavem K. Cutpoints for mild, moderate and severe pain in patients with osteoarthritis of the hip or knee ready for joint replacement surgery. *BMC Musculoskelet Disord* 9(1): 55, 4/2008.
33. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. *Clin J Pain* 20(5): 309-318, 9/2004.
34. Klepstad P, Loge JH, Borchgrevink PC, Mendoza TR, Cleeland CS, Kaasa S. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. *J Pain Symptom Manage* 24(5): 517-525, 11/2002.
35. Krebs EE, Bair MJ, Damush TM, Wu J, Sutherland J, Kroenke K. Development and initial validation of a 3-item brief pain inventory. *Journal of General Internal Medicine* 23: 278-279, 3/2008.
36. Lydick E, Epstein RS, Himmelberger D, White CJ. Area under the curve: a metric for patient subjective responses in episodic diseases. *Qual Life Res* 4(1): 41-45, 2/1995.
37. Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turiziani A, Speranza R, Tassinari D, Magnani P, Saccani D,

Montanari L, Roudnas B, Amadori D, Fabbri L, Nanni O, Rauli P, Poggi B, Fochessati F, Giannunzio D, Barbagallo ML, Minnotti V, Betti M, Giordani S, Piazza E, Scapaticci R, Ferrario S. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. *Support Care Cancer* 13(11): 888-894, 11/2005.

38. Mendoza T, Mayne T, Rublee D, Cleeland C. Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. *Eur J Pain* 10(4): 353-361, 5/2006.
39. Mendoza TR, Chen C, Brugger A, Hubbard R, Snabes M, Palmer SN, Zhang Q, Cleeland CS. The utility and validity of the modified brief pain inventory in a multiple-dose postoperative analgesic trial. *Clin J Pain* 20(5): 357-362, 9/2004.
40. Mystakidou K, Mendoza T, Tsilika E, Befon S, Parpa E, Bellos G, Vlahos L, Cleeland C. Greek brief pain inventory: validation and utility in cancer pain. *Oncology* 60(1): 35-42, 2001.
41. Osborne TL, Raichle KA, Jensen MP, Ehde DM, Kraft G. The reliability and validity of pain interference measures in persons with multiple sclerosis. *J Pain Symptom Manage* 32(3): 217-229, 9/2006.
42. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. *J Clin Oncol* 16(4): 1588-1593, 4/1998.
43. Philip J, Smith WB, Craft P, Lickiss N. Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. *Support Care Cancer* 6(6): 539-541, 11/1998.
44. Poundja J, Fikretoglu D, Guay S, Brunet A. Validation of the French version of the brief pain inventory in Canadian veterans suffering from traumatic stress. *J Pain Symptom Manage* 33(6): 720-726, 6/2007.
45. Puhan MA, Schunemann HJ, Wong E, Griffith L, Guyatt GH. The standard gamble showed better construct validity than

- the time trade-off. *Journal of Clinical Epidemiology* 60(10): 1029-1033, 10/2007.
46. Radbruch L, Loick G, Kiencke P, Lindena G, Sabatowski R, Grond S, Lehmann KA, Cleeland CS. Validation of the German version of the Brief Pain Inventory. *J Pain Symptom Manage* 18(3): 180-187, 9/1999.
 47. Radbruch L, Sabatowski R, Loick G, Jonen-Thielemann I, Elsner F, Hormann E. [MIDOS--validation of a minimal documentation system for palliative medicine]. *Schmerz* 14(4): 231-239, 8/2000.
 48. Raichle KA, Osborne TL, Jensen MP, Cardenas D. The reliability and validity of pain interference measures in persons with spinal cord injury. *J Pain* 7(3): 179-186, 3/2006.
 49. Rutledge DN, Jones CJ. Effects of topical essential oil on exercise volume after a 12-week exercise program for women with fibromyalgia: A pilot study. *Journal of Alternative and Complementary Medicine* 13(10): 1099-1106, 12/2007.
 50. Saxena A, Mendoza T, Cleeland CS. The assessment of cancer pain in north India: the validation of the Hindi Brief Pain Inventory--BPI-H. *J Pain Symptom Manage* 17(1): 27-41, 1/1999.
 51. Seidman AD, Portenoy R, Yao TJ, Lepore J, Mont EK, Kortmanky J, Onetto N, Ren L, Grechko J, Beltangady M, . Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. *J Natl Cancer Inst* 87(17): 1316-1322, 9/1995.
 52. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. *Pain* 61(2): 277-284, 5/1995.
 53. Shin H, Kim K, Young HK, Chee W, Im EO. A comparison of two pain measures for Asian American cancer patients. *West J Nurs Res* 29(5): 545-560, 8/2007.
 54. Shin H, Kim K, Young HK, Chee W, Im EO. A comparison of two pain measures for asian american cancer patients. *West J Nurs Res* 30(2): 181-196, 3/2008.
 55. Smith BH, Torrance N, Bennett MI, Lee AJ. Health and Quality of Life Associated With Chronic Pain of Predominantly Neuropathic Origin in the Community. *Clin J Pain* 23(2): 143-149, 2/2007.
 56. Su L, Tucker R, Frey SE, Gress JO, Chan IS, Kuter BJ, Guess HA. Measuring injection-site pain associated with vaccine administration in adults: a randomised, double-blind, placebo-controlled clinical trial. *J Epidemiol Biostat* 5(6): 359-365, 2000.
 57. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. *J Pain* 5(2): 133-137, 3/2004.
 58. Tittle MB, McMillan SC, Hagan S. Validating the brief pain inventory for use with surgical patients with cancer. *Oncol Nurs Forum* 30(2): 325-330, 3/2003.
 59. Tyler EJ, Jensen MP, Engel JM, Schwartz L. The reliability and validity of pain interference measures in persons with cerebral palsy. *Arch Phys Med Rehabil* 83(2): 236-239, 2/2002.
 60. Tzeng JI, Chang CC, Chang HJ, Lin CC. Assessing Analgesic Regimen Adherence with the Morisky Medication Adherence Measure for Taiwanese Patients with Cancer Pain. *J Pain Symptom Manage*, 4/2008.
 61. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory--BPI-J. *J Pain Symptom Manage* 16(6): 364-373, 12/1998.
 62. Wang XS, Mendoza TR, Gao SZ, Cleeland CS. The Chinese version of the Brief Pain Inventory (BPI-C): its development and use in a study of cancer pain. *Pain* 67(2-3): 407-416, 10/1996.
 63. Williams VS, Smith MY, Fehnel SE. The validity and utility of the BPI interference measures for evaluating the impact of

- osteoarthritic pain. *J Pain Symptom Manage* 31(1): 48-57, 1/2006.
64. Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S. Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France. *Curr Med Res Opin* 23(9): 2035-2042, 9/2007.
 65. Yun YH, Mendoza TR, Heo DS, Yoo T, Heo BY, Park HA, Shin HC, Wang XS, Cleeland CS. Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. *Oncology* 66(6): 439-444, 2004.
 66. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, You CH, West K. Validation of the Korean version of the EORTC QLQ-C30. *Qual Life Res* 13(4): 863-868, 5/2004.
 67. Yun YH, Wang XS, Lee JS, Roh JW, Lee CG, Lee WS, Lee KS, Bang SM, Mendoza TR, Cleeland CS. Validation study of the Korean version of the brief fatigue inventory. *J Pain Symptom Manage* 29(2): 165-172, 2/2005.
 68. Zakrzewska JM, Lopez BC, Kim SE, Varian EA, Coakham HB. Patient satisfaction after surgery for trigeminal neuralgia - development of a questionnaire. *Acta Neurochir (Wien)* 147(9): 925-932, 9/2005.
 69. Zalon ML. Using and understanding factor analysis: the Brief Pain inventory. *Nurse Res* 14(1): 71-84, 2006.
 70. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. *Pain* 115(1-2): 29-36, 5/2005.
 71. Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. *J Pain Symptom Manage* 29(4): 401-410, 4/2005.
 72. Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the Brief Pain Inventory for

painful diabetic peripheral neuropathy. *J Vasc Nurs* 23(3): 97-104, 9/2005.

Language Translations

1. Badia X, Muriel C, Gracia A, Nunez-Olarte JM, Perulero N, Galvez R, Carulla J, Cleeland CS. [Validation of the Spanish version of the Brief Pain Inventory in patients with oncological pain]. *Med Clin (Barc)* 120(2): 52-59, 1/2003.
2. Caraceni A, Mendoza TR, Menciaaglia E, Barattella C, Edwards K, Forjaz MJ, Martini C, Serlin RC, de CF, Cleeland CS. A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). *Pain* 65(1): 87-92, 4/1996.
3. Ger LP, Ho ST, Sun WZ, Wang MS, Cleeland CS. Validation of the Brief Pain Inventory in a Taiwanese population. *J Pain Symptom Manage* 18(5): 316-322, 11/1999.
4. Kalyadina SA, Ionova TI, Ivanova MO, Uspenskaya OS, Kishtovich AV, Mendoza TR, Guo H, Novik A, Cleeland CS, Wang XS. Russian Brief Pain Inventory: validation and application in cancer pain. *J Pain Symptom Manage* 35(1): 95-102, 1/2008.
5. Klepstad P, Loge JH, Borchgrevink PC, Mendoza TR, Cleeland CS, Kaasa S. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. *J Pain Symptom Manage* 24(5): 517-525, 11/2002.
6. Mystakidou K, Mendoza T, Tsilika E, Befon S, Parpa E, Bellos G, Vlahos L, Cleeland C. Greek brief pain inventory: validation and utility in cancer pain. *Oncology* 60(1): 35-42, 2001.
7. Poundja J, Fikretoglu D, Guay S, Brunet A. Validation of the French version of the brief pain inventory in Canadian veterans suffering from traumatic stress. *J Pain Symptom Manage* 33(6): 720-726, 6/2007.
8. Radbruch L, Loick G, Kiencke P, Lindena G, Sabatowski R, Grond S, Lehmann KA, Cleeland CS. Validation of the German version of the Brief Pain Inventory. *J Pain Symptom Manage* 18(3): 180-187, 9/1999.

9. Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F. A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory--BPI-J. *J Pain Symptom Manage* 16(6): 364-373, 12/1998.
10. Wang XS, Mendoza TR, Gao SZ, Cleeland CS. The Chinese version of the Brief Pain Inventory (BPI-C): its development and use in a study of cancer pain. *Pain* 67(2-3): 407-416, 10/1996.
11. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, You CH, West K. Validation of the Korean version of the EORTC QLQ-C30. *Qual Life Res* 13(4): 863-868, 5/2004.

Methods Papers

1. Anderson KO, Syrjala KL, Cleeland CS. How to assess cancer pain. In: Turk DC, Melzack R, editors. *Handbook of Pain Assessment*. New York: Guilford Press; pp. 579-600, 2001.
2. Anderson KO, Cleeland CS. The assessment of cancer pain. In: Bruera E, Portenoy RK, eds. *Cancer Pain: Assessment and Management*. Cambridge, UK: Cambridge University Press; 2003.
3. Anderson KO, Cleeland CS. Assessment of cancer-related symptoms. In: Nelson K, ed. *Palliative Care for the Oncologist*. Totowa, New Jersey: Humana Press; 2003.
4. Aurret KA, Toye C, Goucke R, Kristjanson LJ, Bruce D, Schug S. Development and testing of a modified version of the brief pain inventory for use in residential aged care facilities. *J Am Geriatr Soc* 56(2): 301-306, 2/2008.
5. Barlesi F, Picard M, Astoul P, Villani P. [Pain management of lung cancer patients by general practitioners]. *Therapie* 61(6): 501-505, 11/2006.
6. Broderick JE, Schwartz JE, Vikingstad G, Pribbernow M, Grossman S, Stone AA. The accuracy of pain and fatigue items across different reporting periods. *Pain [Epub]*, 4/2008.

7. Caraceni A. Evaluation and assessment of cancer pain and cancer pain treatment. *Acta Anaesthesiol Scand* 45(9): 1067-1075, 10/2001.
8. Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, de CF. Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. *J Pain Symptom Manage* 23(3): 239-255, 3/2002.
9. Casarett D, Karlawish J, Sankar P, Hirschman K, Asch DA. Designing pain research from the patient's perspective: what trial end points are important to patients with chronic pain? *Pain Med* 2(4): 309-316, 12/2001.
10. Castel LD, Abernethy AP, Li Y, Depuy V, Saville BR, Hartmann KE. Hazards for Pain Severity and Pain Interference with Daily Living, with Exploration of Brief Pain Inventory Cutpoints, Among Women with Metastatic Breast Cancer. *J Pain Symptom Manage* 34(4): 380-92, 6/2007.
11. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. *Cancer* 88(9): 2164-2171, 5/2000.
12. Chang Y, Lin YP, Chang HJ, Lin CC. Cancer patient and staff ratings of caring behaviors: relationship to level of pain intensity. *Cancer Nurs* 28(5): 331-339, 9/2005.
13. Chelminski PR, Ives TJ, Felix KM, Prakken SD, Miller TM, Perhac JS, Malone RM, Bryant ME, DeWalt DA, Pignone MP. A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. *BMC Health Serv Res* 5(1): 3, 1/2005.
14. Clark K, Greaves J, Sung E, Glare P. Development and introduction of a pain score documentation chart in the acute oncology setting. *Asia-Pacific Journal of Clinical Oncology* 3(2): 89-94, 6/2007.
15. Cleeland CS. The impact of pain on the patient with cancer. *Cancer* 54(11 Suppl): 2635-2641, 12/1984.

16. Cleeland CS. Measurement and prevalence of pain in cancer. *Semin Oncol Nurs* 1(2): 87-92, 5/1985.
17. Cleeland CS. How to treat a "construct". *J Pain Symptom Manage* 1(3): 161-162, 1986.
18. Cleeland CS, Ladinsky JL, Serlin RC, Nugyen CT. Multidimensional measurement of cancer pain: comparisons of US and Vietnamese patients. *J Pain Symptom Manage* 3(1): 23-27, 1988.
19. Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, eds. *Issues in Pain Measurement*. New York: Raven Press; pp. 391-403, 1989 *Advances in Pain Research and Therapy*; Vol. 12.
20. Cleeland CS. Pain assessment. In: Lipton S, editor. *Issues in Pain Management*. New York: Raven Press; pp. 287-291, 1990 *Advances in Pain Research and Therapy*; Vol. 12.
21. Cleeland CS. Assessment of pain in cancer: Measurement issues. In: Foley KM, editor. *Advances in Pain Research and Therapy*. New York: Raven Press; pp. 47-55, 1990 Vol. 16.
22. Cleeland CS. Pain Assessment in Cancer. In: Osoba D, editor. *Effect of Cancer on Quality of Life*. Boca Raton: CRC Press; 1991.
23. Cleeland CS, Syrjala KL. How to assess cancer pain. In: Turk D, Melzack R, editors. *Pain Assessment*. New York: Guilford Press; pp. 360-387, 1992.
24. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singapore* 23(2): 129-138, 3/1994.
25. Cleeland CS, Bruera E. Managing Cancer Pain. In: Brain MC, Carbone PP, editors. *Current Therapy in Hematology-Oncology*. St. Louis: Mosby; pp. 571-578, 1995.
26. Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. *Pain* 67(2-3): 267-273, 10/1996.
27. Cleeland CS, Serlin RC, Nakamura Y, Mendoza TR. Effects of culture and language on ratings of cancer pain and patterns of functional interference. In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z, editors. *Progress in Pain Research and Management*. Seattle: IASP Press; pp. 35-51, 1997 *Proceedings of the 8th World Congress on Pain*; Vol. 8.
28. Cleeland CS. Pain assessment: the advantages of using pain scales in lysosomal storage diseases. *Acta Paediatr Suppl* 91(439): 43-47, 2002.
29. Cleeland CS, Anderson KO. Assessment of cancer-related symptoms: relevance for CAM research methodology. In: *Expert Opinions on Methodology: Development of Cancer CAM Symptom Research*, Publication No. 03-5427 [Final Report From the Expert Panel on Symptom Research, Nov 29-30, 2001]. Bethesda, MD: National Cancer Institute; pp. 67-90, 9/2003.
30. Cook K, Johnson K, Amtmann D. (936): The impact on reliability of scoring the brief pain inventory interference scale with fewer than eleven categories. *The Journal of Pain* 7(4, Supplement 1): S83, 4/2006.
31. Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. *Cancer* 50(9): 1913-1918, 11/1982.
32. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. *Pain* 17(2): 197-210, 10/1983.
33. Donovan KA, Taliaferro LA, Brock CW, Bazargan S. Sex Differences in the Adequacy of Pain Management among Patients Referred to a Multidisciplinary Cancer Pain Clinic. *J Pain Symptom Manage*, 4/2008.
34. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmadder KE, Stacey

- BR, Stauffer JW, von ST, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain* 9(2): 105-121, 2/2008.
35. Ewing G, Todd C, Rogers M, Barclay S, McCabe J, Martin A. Validation of a symptom measure suitable for use among palliative care patients in the community: CAMPAS-R. *J Pain Symptom Manage* 27(4): 287-299, 4/2004.
 36. Ferreira KA, Kimura M, Teixeira MJ, Mendoza TR, da Nobrega JC, Graziani SR, Takagaki TY. Impact of Cancer-Related Symptom Synergisms on Health-Related Quality of Life and Performance Status. *J Pain Symptom Manage*, 3/2008.
 37. Franneby U, Gunnarsson U, Andersson M, Heuman R, Nordin P, Nyren O, Sandblom G. Validation of an Inguinal Pain Questionnaire for assessment of chronic pain after groin hernia repair. *Br J Surg* 95(4): 488-493, 4/2008.
 38. Gjeilo KH, Stenseth R, Wahba A, Lydersen S, Klepstad P. Validation of the Brief Pain Inventory in Patients Six Months After Cardiac Surgery. *J Pain Symptom Manage* 34(6): 648-656, 12/2007.
 39. Gunnarsdottir S, Serlin RC, Ward S. Patient-related barriers to pain management: the Icelandic Barriers Questionnaire II. *J Pain Symptom Manage* 29(3): 273-285, 3/2005.
 40. Hadjistavropoulos T, Herr K, Turk DC, Fine PG, Dworkin RH, Helme R, Jackson K, Parmelee PA, Rudy TE, Lynn BB, Chibnall JT, Craig KD, Ferrell B, Ferrell B, Fillingim RB, Gagliese L, Gallagher R, Gibson SJ, Harrison EL, Katz B, Keefe FJ, Lieber SJ, Lussier D, Schmader KE, Tait RC, Weiner DK, Williams J. An Interdisciplinary Expert Consensus Statement on Assessment of Pain in Older Persons. *Clin J Pain* 23 Suppl 1: S1-S43, 1/2007.
 41. Hojsted J, Nielsen PR, Eriksen J, Hansen OB, Sjogren P. Breakthrough pain in opioid-treated chronic non-malignant pain patients referred to a multidisciplinary pain centre: a preliminary study. *Acta Anaesthesiol Scand* 50(10): 1290-1296, 11/2006.
 42. Holen JC, Hjermstad MJ, Loge JH, Fayers PM, Caraceni A, de CF, Forbes K, Furst CJ, Radbruch L, Kaasa S. Pain Assessment Tools: Is the Content Appropriate for Use in Palliative Care? *J Pain Symptom Manage* 32(6): 567-580, 12/2006.
 43. Holen JC, Lydersen S, Klepstad P, Loge JH, Kaasa S. The Brief Pain Inventory: Pain's Interference With Functions Is Different in Cancer Pain Compared With Noncancer Chronic Pain. *Clin J Pain* 24(3): 219-225, 3/2008.
 44. Hwang SS, Chang VT, Kasimis B. Dynamic cancer pain management outcomes: the relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time. *J Pain Symptom Manage* 23(3): 190-200, 3/2002.
 45. Jensen MP, Keefe FJ, Lefebvre JC, Romano JM, Turner JA. One- and two-item measures of pain beliefs and coping strategies. *Pain* 104(3): 453-469, 8/2003.
 46. Jensen MP, Dworkin RH, Gammaitoni AR, Olaleye DO, Oleka N, Galer BS. Do Pain Qualities and Spatial Characteristics Make Independent Contributions to Interference With Physical and Emotional Functioning? *J Pain* 7(9): 644-653, 9/2006.
 47. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. *Clin J Pain* 20(5): 309-318, 9/2004.
 48. Krebs EE, Carey TS, Weinberger M. Accuracy of the pain numeric rating scale as a screening test in primary care. *J Gen Intern Med* 22(10): 1453-1458, 10/2007.
 49. Krebs EE, Bair MJ, Damush TM, Wu J, Sutherland J, Kroenke K. Development and initial validation of a 3-item brief pain inventory. *Journal of General Internal Medicine* 23: 278-279, 3/2008.
 50. Lang E. [Structure quality of independent physicians for pain management--is there a standard?]. *Schmerz* 14(4): 226-230, 8/2000.

51. Li KK, Harris K, Hadi S, Chow E. What should be the optimal cut points for mild, moderate, and severe pain? *Journal of Palliative Medicine* 10(6): 1338-1346, 12/2007.
52. Li KK, Hadi S, Kirou-Mauro A, Chow E. When should we define the response rates in the treatment of bone metastases by palliative radiotherapy? *Clin Oncol (R Coll Radiol)* 20(1): 83-89, 2/2008.
53. Li KK, Harris K, Hadi S, Chow E. What should be the optimal cut points for mild, moderate, and severe pain? *J Palliat Med* 10(6): 1338-1346, 12/2007.
54. Li KK, Hadi S, Kirou-Mauro A, Chow E. When should we define the response rates in the treatment of bone metastases by palliative radiotherapy? *Clin Oncol (R Coll Radiol)* 20(1): 83-89, 2/2008.
55. Lydick E, Epstein RS, Himmelberger D, White CJ. Area under the curve: a metric for patient subjective responses in episodic diseases. *Qual Life Res* 4(1): 41-45, 2/1995.
56. McDonald DD, Poudrier S, Gonzalez T, Brace J, Lakhani K, Landry S, Wrigley P. Pain problems in young adults and pain reduction strategies. *Pain Manag Nurs* 3(3): 81-86, 9/2002.
57. McGillis HL, Doran D, Baker GR, Pink GH, Sidani S, O'Brien-Pallas L, Donner GJ. Nurse staffing models as predictors of patient outcomes. *Med Care* 41(9): 1096-1109, 9/2003.
58. Miaskowski C, Dodd M, West C, Paul SM, Schumacher K, Tripathy D, Koo P. The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management. *Pain* 129(1-2): 55-63, 5/2007.
59. Philip J, Smith WB, Craft P, Lickiss N. Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. *Support Care Cancer* 6(6): 539-541, 11/1998.
60. Puhan MA, Schunemann HJ, Wong E, Griffith L, Guyatt GH. The standard gamble showed better construct validity than

the time trade-off. *Journal of Clinical Epidemiology* 60(10): 1029-1033, 10/2007.

61. Radbruch L, Sabatowski R, Loick G, Jonen-Thielemann I, Kasper M, Gondek B, Lehmann KA, Thielemann I. Cognitive impairment and its influence on pain and symptom assessment in a palliative care unit: development of a Minimal Documentation System. *Palliat Med* 14(4): 266-276, 7/2000.
62. Radbruch L, Sabatowski R, Loick G, Jonen-Thielemann I, Kasper M, Gondek B, Lehmann KA, Thielemann I. Cognitive impairment and its influence on pain and symptom assessment in a palliative care unit: development of a Minimal Documentation System. *Palliat Med* 14(4): 266-276, 7/2000.
63. Radbruch L, Sabatowski R, Loick G, Jonen-Thielemann I, Elsner F, Hormann E. [MIDOS--validation of a minimal documentation system for palliative medicine]. *Schmerz* 14(4): 231-239, 8/2000.
64. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. *Pain* 61(2): 277-284, 5/1995.
65. Shacham S, Reinhardt LC, Raubertas RF, Cleeland CS. Emotional states and pain: intraindividual and interindividual measures of association. *J Behav Med* 6(4): 405-419, 12/1983.
66. Shacham S, Dar R, Cleeland CS. The relationship of mood state to the severity of clinical pain. *Pain* 18(2): 187-197, 2/1984.
67. Stenseth G, Bjornes M, Kaasa S, Klepstad P. Can cancer patients assess the influence of pain on functions? A randomised, controlled study of the pain interference items in the Brief Pain Inventory. *BMC Palliat Care* 6(1): 2, 3/2007.
68. Stroud MW, Turner JA, Jensen MP, Cardenas DD. Partner responses to pain behaviors are associated with depression and activity interference among persons with chronic pain and spinal cord injury. *J Pain* 7(2): 91-99, 2/2006.

69. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. *J Pain* 5(2): 133-137, 3/2004.
70. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, You CH, West K. Validation of the Korean version of the EORTC QLQ-C30. *Qual Life Res* 13(4): 863-868, 5/2004.
71. Zalon ML. Using and understanding factor analysis: the Brief Pain inventory. *Nurse Res* 14(1): 71-84, 2006.